



# HHS Public Access

Author manuscript

*Mol Cell Neurosci.* Author manuscript; available in PMC 2018 May 02.

Published in final edited form as:

*Mol Cell Neurosci.* 2016 June ; 73: 13–31. doi:10.1016/j.mcn.2015.11.010.

## Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells

Alison E. Mungenast<sup>1,2,\*</sup>, Sandra Siegert<sup>1,2,3,4,\*</sup>, and Li-Huei Tsai<sup>1,2</sup>

<sup>1</sup>Picower Institute for Learning and Memory, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA

<sup>2</sup>Department of Brain and Cognitive Sciences, MIT, Cambridge, MA, USA

### Abstract

In the last decade, induced pluripotent stem (iPS) cells have revolutionized the utility of human *in vitro* models of neurological disease. The iPS-derived and differentiated cells allow researchers to study the impact of a distinct cell type in health and disease as well as performing therapeutic drug screens on a human genetic background. In particular, clinical trials for Alzheimer's disease (AD) have been often failing. Two of the potential reasons are first, the species gap involved in proceeding from initial discoveries in rodent models to human studies, and second, an unsatisfying patient stratification, meaning subgrouping patients based on the disease severity due to the lack of phenotypic and genetic markers. iPS cells overcome this obstacles and will improve our understanding of disease subtypes in AD. They allow researchers conducting in depth characterization of neural cells from both familial and sporadic AD patients as well as preclinical screens on human cells.

In this review, we briefly outline the *status quo* of iPS cell research in neurological diseases along with the general advantages and pitfalls of these models. We summarize how genome-editing techniques such as CRISPR/Cas will allow researchers to reduce the problem of genomic variability inherent to human studies, followed by recent iPS cell studies relevant to AD. We then focus on current techniques for the differentiation of iPS cells into neural cell types that are relevant to AD research. Finally, we discuss how the generation of three-dimensional cell culture systems will be important for understanding AD phenotypes in a complex cellular milieu, and how both two- and three-dimensional iPS cell models can provide platforms for drug discovery and translational studies into the treatment of AD.

---

<sup>4</sup>To whom correspondence should be addressed: ssiegert@ist.ac.at.

<sup>3</sup>Current address: Institute of Science and Technology, IST, Klosterneuburg, Austria

\*Contributed equally

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## 1. Introduction

**Alzheimer's disease (AD)** is an age-related neurodegenerative disorder associated with severe memory impairments and has become the 6<sup>th</sup> leading cause of death in the United States ([www.alz.org](http://www.alz.org)). The first case of AD was published in 1907 by Dr. Aloysius "Alois" Alzheimer, who described a 51-year-old woman with serious memory loss. Post-mortem analysis of her brain showed severe brain atrophy and neuronal loss, as well as the presence of dense extracellular deposits and intracellular aggregates within neurons (Alzheimer, 1911; Graeber, et al., 1997). These features were eventually identified as amyloid plaques and neurofibrillary tangles, respectively (Glennner and Wong, 1984; Grundke-Iqbal, et al., 1986; Kosik, et al., 1986), and the condition became known as Alzheimer's Disease (Kraepelin, 1910).

Amyloid plaques are extracellular accumulations of  $\beta$ -amyloid ( $A\beta$ ) peptides that are derived from the proteolytic processing of the  $\beta$ -amyloid precursor protein (APP) (Goldgaber, et al., 1987; Kang, et al., 1987; Robakis, et al., 1987; Tanzi, et al., 1987). The  $\gamma$ -secretase complex cleaves APP at different positions, generating different size amyloidogenic peptides  $A\beta_{43}$ ,  $A\beta_{42}$ ,  $A\beta_{40}$ ,  $A\beta_{38}$ , and  $A\beta_{37}$  (De Strooper, 2010). Of these,  $A\beta_{40}$  is the most abundant in both healthy and AD brain tissue, whereas the  $A\beta_{42}$  variant has been shown to be likely the most deleterious (Jarrett, et al., 1993; Portelius, et al., 2010). Much of our understanding of the mechanisms underlying AD pathology comes from a small population of individuals with early-onset familial AD (fAD). These cases harbor causal mutations involving primarily the  $A\beta$  processing enzymes, presenilin 1 and 2 (*PSEN1*, *PSEN2*), which are part of the  $\gamma$ -secretase complex (Levy-Lahad, et al., 1995; Levy-Lahad, et al., 1995; Rogaev, et al., 1995; Schellenberg, et al., 1993), or mutations within or duplications of the APP gene itself (Goate, et al., 1991; Goate, 2006; St George-Hyslop, et al., 1987).

The second defining characteristic of AD is the presence of neurofibrillary tangles (NFTs) comprised of intracellular accumulations of the microtubule-associated protein tau in affected neurons (Ballatore, et al., 2007). The extent of tau pathology in human AD has been shown to correlate well to disease severity (Braak and Braak, 1991). Mutations in the gene encoding tau (*MAPT*) have been found to be causal for fronto-temporal dementia, although *MAPT* mutations have not been described in AD (Hutton, et al., 1998; Spillantini, et al., 1998). Overexpression of tau protein in mouse models has been shown to disrupt intracellular trafficking (Zhang, et al., 2006), to induce axonal degeneration (Spittaels, et al., 1999), and the humanized tau overexpression leads to neurofibrillary tangles formation *in vivo* (for review, see (Götz, et al., 2007)). A number of promising drugs have reached late-stage (Phase III) clinical testing, however then failed to prevent cognitive decline (Doody, et al., 2013; Doody, et al., 2014; Salloway, et al., 2014). The reasons are likely twofold: first, the lack of human data for the successful stratification (separating patient population) according to disease phenotypes and/or genetic risk profiles (Blennow, 2010; Wolozin, 2012), and second, the species gap. Risk factors present in humans may not be adequately modeled in rodents. For example, while variants in the *APOE* gene are the strongest genetic risk factors for sporadic AD identified to date (Bertram, et al., 2008; Corder, et al., 1993; Farrer, et al., 1997), the rodent genome has only one version of this gene.

A number of elegant mouse models have allowed the study of AD phenotypes *in vivo* in the brain, and have resulted in the basis of our current mechanistic understanding of the disease. However, a common drawback to these models is that they typically only capture specific aspects of AD phenotypes such as A $\beta$  or NFTs, but rarely the entire disease spectrum (Webster, et al., 2014). Moreover, most mouse models focus only on the causative mutations in familial AD (fAD), such as those in the genes encoding presenilin 1 and 2 (*PSEN1*, *PSEN2*) and the amyloid-precursor protein (*APP*). These cases represent an extremely small percentage of the overall human AD burden; though models of fAD are invaluable, the majority of AD cases are sporadic (sAD). The genetic underpinnings of sAD may result from a combinatorial or additive effect of single nucleotide polymorphisms (SNPs) identified in genome-wide association studies (GWAS) (Lambert, et al., 2013), while disease penetrance may depend on a host of non-genetic risk factors, such as age, head trauma, diabetes, lifetime stress, and environmental toxins, amongst others. Studying the distinct impact of AD-associated SNPs in mouse models is challenging, as these variants are often found in non-coding regions of the human genome. Using even the latest and most rapid genome editing techniques to insert multiple SNPs in homologous mouse genome regions would be onerous, expensive, and could be considered a highrisk undertaking. It is often not known whether a single SNP is disease causing, or whether it's a combination of several SNPs particularly as a number of different SNPs are commonly ascribed to a single locus.

## 2. Human induced pluripotent stem (iPS) cells

We will summarize the history, generation, and differentiation of human iPS cells only briefly, as many excellent reviews have covered these topics (Bouwman and de Laat, 2015; Parent and Anderson, 2015; Telias and Ben-Yosef, 2014). One fundamental question in the regeneration field is to find cells that maintain the capability to differentiate into the three germ layers: endoderm, mesoderm, and ectoderm. Embryonic stem (ES) cells have this “pluripotency” capability (Evans and Kaufman, 1981; Martin, 1981; Thomson, et al., 1998). However, ethical issues tempered the initial excitement for human ES cells and therefore alternative strategies were needed (Hotta, 2008; Kamm, 2005). An important step was the discovery that the content of an oocyte's cytoplasm contained factors crucial for reprogramming somatic cells to an embryonic-like stage (Cowan, et al., 2005; Tada, et al., 2001; Wilmut, et al., 1997). Takahashi *et al.* screened 24 of these factors and demonstrated that Oct3/4, Sox2, c-Myc, and Klf4 induced pluripotent stem cells from adult mouse fibroblasts (Takahashi and Yamanaka, 2006). A year later, the same group showed that they could reprogram human fibroblasts with these four “Yamanaka factors” into human pluripotent stem cells (Takahashi, et al., 2007). Other groups have generated similarly pluripotent cells from other peripheral cells, such as blood cells (Okita, et al., 2013) or urine-derived epithelial cells (Zhou, et al., 2012). To distinguish these pluripotent stem cells from ES cells, the cells were named “induced pluripotent stem” (iPS) cells. Currently, much debate exists over the best method for reprogramming somatic cells into iPS cells, as well as how to assess the “stemness” of an iPS cell as compared to an ES cell line (Bock, et al., 2011; Hanna, et al., 2010; Lister, et al., 2011). It is important to keep in mind that exogenous factors, genetic background, and epigenetic of tissue origin of cells influences naïve pluripotency (Hanna, et al., 2010). Therefore certain differences on the epigenetic landscape

are expected to exist between ES and iPS cells (Bock, et al., 2011; Lister, et al., 2011). Nevertheless, the advent of iPS cells allows to generate any cell type of interest from a patient's own somatic cells and to develop patient-specific drug treatments. Moreover, these techniques offer a nearly unlimited supply of human cells that can be deposited in repositories and shared between laboratories.

### 3. Advantages to modeling neurological disease with iPS cells

The study of human brain disease is hampered by obtaining live material. The ability to generate neural cultures from post-mortem human brains depends greatly on the quality of the post-mortem brain tissue (Verwer, et al., 2002). Prolonged agonal states such as hypoxia, coma, or ischemic brain damage could add confounding variables to these studies (Monoranu, et al., 2009). This is not to mention the sheer difficulty of gaining access to reliable sources of human brain tissue. The generation of human iPS cells is one way to surmount these limitations. Protocols have been developed to differentiate iPS cells *in vitro* into distinct cell types allowing researchers to examine disease onset and progression directly in a human culture model (see Fig. 1) (Liu et al., 2012; Sandoe and Eggan, 2013). A number of studies have shown successful reprogramming of iPS cells from fibroblasts derived from individuals with various neurological diseases such as amyotrophic lateral sclerosis (Dimos, et al., 2008), familial dysautonomia (Lee, et al., 2009), Parkinson's disease (Park, et al., 2008; Soldner, et al., 2009), Rett syndrome (Marchetto, et al., 2010), schizophrenia (Brennand, et al., 2011), spinal muscular atrophy (Ebert, et al., 2009; Yoshida, et al., 2015), ADA-SCID, Gaucher disease type III, Duchenne muscular dystrophy, Becker muscular dystrophy, Down syndrome, Juvenile diabetes mellitus, Huntington disease (Consortium, 2012; Zhang, et al., 2010), and Lesch-Nyhan syndrome (Mattis, et al., 2015; Park, et al., 2008) and AD (Choi, et al., 2014; Hossini, et al., 2015; Iovino, et al., 2015; Israel, et al., 2012; Koch, et al., 2012; Kondo, et al., 2013; Muratore, et al., 2014; Wren, et al., 2015; Yagi, et al., 2011; Table 1).

### 4. Drawbacks of iPS cells in neurological disease modeling

The explosion in human iPS cell use has underscored the need to establish standardized protocols, as cell handling and other factors can influence phenotypes (Boulting, et al., 2011). For example, variable X-inactivation in cells from female donors can have an impact upon both differentiation and phenotype (Boulting, et al., 2011). Also, there is still debate regarding to what extent DNA methylation profiles, and other epigenetic attributes, might be maintained in iPS cells after reprogramming (Kim, et al., 2010; Koche, et al., 2011; Nazor, et al., 2012; Ohi, et al., 2011). To determine the magnitude and nature of variability amongst human iPS cells, (Bock, et al., 2011) performed a human genome-wide reference mapping of the DNA methylation across 20 ES and 12 iPS cell lines. They established two scorecards for evaluating the quality and utility of human pluripotent cell lines; this kind of tool is crucial to the standardization of iPS protocols and is needed to obtain comparable and reproducible results.

Genetic diversity within and between populations, as well as disease onset and progression, can impact the experimental read-out from iPS cells (Rouhani, et al., 2014; Soldner and

Jaenisch, 2012). For example, common DNA variants may alter expression levels and pattern of many human genes (Majewski and Pastinen, 2011). Some groups have sought to overcome this diversity by focusing either on few phenotypes in a large collection of lines (Bock, et al., 2011; Rouhani, et al., 2014; Yoshimizu, et al., 2015), or by investigating robust phenotypes in a smaller cohort (Chung, et al., 2013; Israel, et al., 2012). Each iPS cell study is challenged by the question of to what extent the observed phenotypes are related to the disease being modeled. For example, is the phenotype influenced by protective or exacerbating factors in the individual's genotype? Recent advances in genome editing techniques, particularly the use of Cas9 nuclease-based strategies, have made the generation of isogenic iPS cell practicable (F. Zhang et al., 2014; Y. Zhang et al., 2014; D. Zhang et al., 2014) and this technology can address the variability inherent in the human genome to some extent.

## 5. Creating isogenic iPS cell lines as a strategy to overcome variability in human genomes

The advent of homology-directed repair techniques for genome editing proved a major advance in our ability to manipulate the human genome. Currently, three systems have been established to perform DNA repair-directed genome editing: Zinc-Finger-Nucleases (ZFN), transcription activator-like effector nucleases (TALENs), and the clustered regularly interspaced short palindromic repeats (CRISPR) system that uses the Cas9 nuclease. All these nucleases induce guided DNA breaks. The repair of these breaks then either leads to insertion or deletion (indel) mutations, or the break can be repaired by homologous recombination with a donor vector carrying the desired mutation (Byrne, et al., 2014). For a detailed review of the function of each of the nucleases, please refer to the reviews from (Hsu, et al., 2014; Sander and Joung, 2014) as well as to descriptions of experimental strategies and protocols for human pluripotent cells in particular (Byrne, et al., 2014; Chiba and Hockemeyer, 2015; Zhu, et al., 2014).

The first generation of enzyme-directed genome editing used ZFNs. A number of important papers used the first generation ZFNs to generate isogenic iPS cells (Carroll, 2011; Urnov, et al., 2010) by knocking down genes such as *PITX3* (Hockemeyer, et al., 2009) or *PIG-A* (Zou, et al., 2009), or correcting disease-related mutations in genes such as  $\alpha$ 1-anti-trypsin (Yusa, et al., 2011),  $\alpha$ -synuclein (*SCNA*), (Ryan, et al., 2013; Soldner, et al., 2011), and tau (*MAPT*) (Fong, et al., 2013). However, the success of this technique is limited due to the challenging design of a robust engineered zinc finger nuclease (Hsu, et al., 2014; Ma, et al., 2015; Sander and Joung, 2014). The development of the second generation TALEN technique overcame some of the limitations of the ZFNs by being less context-dependent and easier to design (Joung and Sander, 2013; Miller, et al., 2011; Sander and Joung, 2014), while the efficiency is similar between the two paradigms (Hockemeyer, et al., 2011). Human iPS models established with TALEN technology include manipulations in the *APOB*, *SORT1*, *AKT2*, *PLIN1* (Ding, et al., 2013), *PSENI* (Woodruff, et al., 2013), and *DISC1* (Wen, et al., 2014). The third generation of genome editing tools is comprised of the CRISPR/Cas9 systems, which are based on the use of the RNA-guided Cas9 nuclease (Jinek, et al., 2012; Mali, et al., 2013; Ran, et al., 2013). One major advantage of the

CRISPR system is that the Cas9 component is fixed, and the targeting sequence is supplied via a single-guide RNA (sgRNA); thus, targeting sequences can be easily exchanged or multiplexed by testing multiple sgRNAs (Ding, et al., 2013). Several groups generated iPS cells that stably or inducible express the Cas9 protein. This system allows for rapid cell-based screens to test the consequences of multiple gene knockdowns using sgRNA libraries (Shalem, et al., 2014; Wang, et al., 2014; Zhu, et al., 2014). Algorithms have been developed that predict off target effects of CRISPR-mediated genome editing, which, combined with falling costs for deep sequencing, allow researchers to minimize off-target effects (Hsu et al., 2013; Tsai et al., 2015; Slaymaker et al., 2015).

The advantage of isogenic lines is that only the disease-associated difference is studied, as the genetic background of the lines should be identical. While this is ideal for the study of disease causative mutations, other genetic variants, such as a haplotype of SNPs, are more difficult to model because they may only be relevant to disease risk in combination. Therefore, it seems advisable to both correct the mutation of interest in a patient-derived cell line, while in parallel introducing it in a control line. Techniques using mutated Cas9 linked to transcriptional activators or repressors also allow us to examine the consequences of enhanced or suppressed expression of specific genes without alterations to the genome itself (Qi, et al., 2013). Therefore, genome editing will be an important strategy to minimize the effect of background variations in human iPS cell-derived lines.

## 6. iPS cells as a model for understanding AD onset and disease progression

In the following chapter, we will focus on studies that use iPS cells to model AD-like phenotypes (summarized in Table 1). The two hallmark characteristics of AD in the human brain are first, accumulation of  $\beta$ -amyloid ( $A\beta$ ) peptides into extracellular aggregates ( $A\beta$  plaques), and second, the intracellular accumulation of phosphorylated species of the microtubule-associated protein tau into neurofibrillary tangles (NFTs). Both parameters can be measured *in vitro*: alterations in the presence of  $A\beta$  peptides can be measured from culture medium or cell lysates, and the ratios between different species of  $A\beta$  peptides, such as the amount of  $A\beta_{40}$  versus  $A\beta_{42}$ , are often reported. To examine tauopathy in AD cellular models, the abundance of different species of phosphorylated tau (pTau) is normalized against total tau levels. Other AD-like phenotypes that can be measured in cultured cells will also be discussed, including endosome cycling and DNA damage.

### 6.1. Phenotypic characterization of iPS cell AD models

Several groups have succeeded in creating functional neurons from fAD and sAD iPS cells: In 2011, Yagi et al. used fibroblasts of fAD patients with mutations in either presenilin isoform PSEN1 (A246E) or PSEN2 (N141I; Yagi, et al., 2011). Using retrovirus carrying a five-factor reprogramming mix of OCT4, SOX2, KLF4, LIN28 and NANOG, they created iPS cells that were then differentiated mainly into neuronal cells. After two-week culturing, they observed an elevated ratio of  $A\beta_{42}$  to  $A\beta_{40}$  for the fAD lines compared to controls. The authors did not find any level of tauopathy, and speculated that the two-week maturation time may have been too short. Treatment of the cultures with the  $\gamma$ -secretase inhibitors



Compound E and Compound W reduced both A $\beta$ <sub>40</sub> and A $\beta$ <sub>42</sub> levels, while only the highest dose of Compound W appeared to impact the A $\beta$ <sub>42</sub>/40 ratio. This study was the first to establish a model of fAD phenotypes in iPS cell-derived neural cultures. However the drawbacks of this work might be the relatively short time of neuron maturation as well as the potential high variability between clones of the same genotype.

In 2012, Israel et al. provided a thorough evaluation of AD-like phenotypes in multiple iPS cell-derived neurons from both fAD and sAD individuals (Israel, et al., 2012). They used retrovirus carrying the four Yamanaka factors OCT4, SOX2, KLF4, and c-MYC to create iPS cell lines from healthy, non-demented individuals, two sporadic AD patients, and two familial patients, who carried APP duplications. Neural progenitor cells were purified using fluorescence activated cell sorting and differentiated into heterogeneous neuronal cultures. They observed increased secreted A $\beta$ <sub>40</sub> in neurons created from one sAD and the two fAD lines. Importantly, the A $\beta$  levels did not differ in fibroblasts from the same individuals, supporting the idea that only distinct iPS-derived cells can model disease-specific phenotypes. No changes were observed in the A $\beta$ <sub>42</sub>/40 or A $\beta$ <sub>38</sub>/40 ratios between cell lines, although the authors noted that detection of the less abundant A $\beta$ <sub>42</sub> and A $\beta$ <sub>38</sub> species were often below the detection range of the assay due to the small number of neurons. In a similar pattern, one sAD and both fAD lines showed increased phospho-tau and activation of the tau kinase GSK3 $\beta$ . Treatment of the neuronal cultures with  $\gamma$ - and  $\beta$ -secretase inhibitors reduced A $\beta$ <sub>40</sub> in one sAD and one fAD line, while only  $\beta$ -secretase inhibitors lowered the levels of active GSK-3 $\beta$ , and phospho-tau. Another AD phenotype that can be characterized in iPS cell-derived cultures is the presence of abnormal endosomes. Large, RAB5-positive early endosomes have been observed in AD mouse models and in the brains of sAD and fAD patients (Cataldo, et al., 2001; Cataldo, et al., 2000). These endosomes may contain aberrantly phosphorylated A $\beta$  (Lee, et al., 2003). Impaired endocytic and mitochondrial trafficking has also been observed in iPS cell models of frontotemporal dementia (FTD) using cells from patients carrying mutations in the MAPT gene (Iovino, et al., 2015; Wren, et al., 2015). Israel *et al.* examined early endosome morphology in iPS-derived neurons seeded onto a layer of commercially-available human astrocytes, and found that the number of medium to large RAB5+ endosomes was increased in neurons derived from one sAD and one fAD compared to the two controls, when they examined early endosome morphology in iPS-derived neurons seeded onto a layer of commercially-available human astrocytes. Finally, they measured synapse formation and function. No differences were apparent in synapse number (synapsin immunoreactivity) or function (voltage clamp recordings) between the AD and control lines.

In 2013, Kondo et al. used episomal vectors to generate iPS cells from dermal fibroblasts from both sAD patients and fAD patients carrying the APP-V717L or the APP-E693 fAD mutations (Kondo, et al., 2013). The E693 mutation leads to early-onset AD, but without amyloid deposition. Differentiated E693 neurons showed decreased A $\beta$ <sub>40</sub> and A $\beta$ <sub>42</sub> compared to controls, while neurons from the V717L line have increased extracellular A $\beta$  and an increased A $\beta$ <sub>42</sub>/40 ratio. No significant A $\beta$  secretion was detectable in the medium of the sAD lines. The authors then established astrocyte-rich cultures using protocols modified from Su-Chun Zhang's work (Krencik and Zhang, 2011). Astrocytes from the E693 line and one of the sAD lines accumulated A $\beta$  oligomers intracellular. They performed gene

expression profiling of the astrocyte/neuronal co-cultures from E693 and control cells and observed that oxidative stress-related categories were upregulated in the AD lines, suggesting ER and Golgi perturbation. The levels of these genes were reduced following treatment with DHA, known to alleviate oxidative stress, as well as the production of ROS, in E693 cells, without altering the levels of A $\beta$ .

Fong et al (2013) used zinc-finger nucleases (ZFNs) to correct a A152T mutation in the *MAPT* gene (tau), as well as to create an isogenic line homozygous for the mutation, in iPS cells (Fong, et al., 2013). Following neuronal differentiation, the heterozygous mutant tau neurons showed short, misshapen neurites with punctate tau and significant phospho-tau immunoreactivity. These phenotypes were absent in the corrected lines, and were significantly exacerbated in the homozygous mutant lines, which showed high degrees of phospho-tau (AT8) and blebbing of the neurites. While they found a low percentage of dopaminergic cells (DA) in the mutant lines, the corrected isogenic lines had 4 to 8-fold increased number of DA neurons.

In addition to lines derived from AD patients, several groups have overexpressed fAD mutant versions of PSEN1 or APP in healthy iPS or ES cell lines (Choi, et al., 2014; Koch, et al., 2012). For example, neurons created from a human ES cell line were transduced, as neuroepithelial-like stem cells, with lentivirus carrying cDNAs for PSEN1<sub>wt</sub>, PSEN1<sub>D385N</sub>, or PSEN1<sub>L166P</sub> under control of the EF1 $\alpha$  promoter (Koch, et al., 2012). By four weeks of neuronal differentiation, most of the  $\beta$ -III tubulin-positive cells were highly immunoreactive for APP. Interestingly, the inclusion of Exon 15 of APP, a splice variant associated with neurons, was present in neurons after 4 weeks compared to undifferentiated cells. Extracellular A $\beta$  level was reduced in these neuronal cultures following treatment with the  $\gamma$ -secretase inhibitor DAPT. In addition, NSAIDs, such as ibuprofen, slightly lowered A $\beta$  levels only in the PS1<sub>wt</sub>, but not the PS1<sub>D385N</sub>, overexpressing neurons. One early screening effort used commercially available iPS cell-derived neurons (iCell Neurons) to screen a library of several hundred compounds for their ability to ameliorate toxicity from exogenously applied A $\beta$  (Xu, et al., 2013).

To date, most studies model AD in patient-derived iPS cells utilize cell lines with defined fAD mutations in PSEN1 and APP. While some studies include cells from sAD patients, the lack of a defined mutation means that isogenic lines cannot be made, and often information is lacking as to the severity or course of disease progression. Two studies in which sAD lines were included observed disease phenotypes similar to fAD cells in only one of two sAD samples (Israel, et al., 2012; Kondo, et al., 2013). Few studies include sAD lines, and this is a concern, as sporadic late-onset AD represents the vast majority of AD cases. And while 60–80% of sAD may in fact have genetic underpinnings (Gatz, et al., 2006), one's *APOE* genotype remains the only robust factor affecting sAD risk. These issues add to the call for development of AD biomarkers that can predict disease risk and age of onset. Much work has begun in this direction, and large-scale human genome-wide association studies (GWAS) combined with mouse and human epigenetic and transcriptome profiling, have derived lists of genes in which variants are consistently associated with an increased risk of AD (Bertram, et al., 2007). These genes tend to be implicated in vesicle trafficking/endocytosis, immune function, and cholesterol metabolism (for review see Olgiati, et al., 2011)). One



recent study (Young, et al., 2015) focused upon iPS cells derived from individuals with sAD-associated variants in the *SORL1* gene, which encodes a protein involved in endocytic trafficking, and whose loss of expression has been observed in sAD brains. The authors found that the induction of *SORL1* expression by brain-derived neurotrophic factor (BDNF) treatment, as well as the effect of *SORL1* expression upon A $\beta$  secretion, was affected by *SORL1* genotype in differentiated human neurons. While these studies were hampered by significant variability, which was combated by the inclusion of a relatively large number of cell lines, it was the first to describe a phenotype in human iPS cell-derived neurons resulting from sAD-associated genetic variants. With the increased feasibility of genome editing in iPS cells, particularly to create point mutations, we anticipate that the near future will see many more reports elucidating the roles of sAD risk variants in iPS cell-derived neural cell models.

## 6.2. AD phenotypes in Down syndrome iPS cells

Down Syndrome (DS) patients show a high incidence of early-onset AD-like dementia (40–60%). The underlying reasons for this are not clear, but are presumably related to the triplication of the *APP* gene, as well as the tau kinase *Dyrk1a* gene (Woods, et al., 2001) on chromosome 21 (Beyreuther, et al., 1993; Burger and Vogel, 1973; Lemere, et al., 1996; Rumble, et al., 1989). Therefore, neural cell models from DS individuals may improve both our understanding of AD-like pathology, as well as providing hope for therapies for DS (2013). To date, no genome editing protocols have been reported that allow for the correction or induction of trisomy in iPS cell models. However, the rare occurrence of monozygotic twins discordant for trisomy 21 (Hibaoui, et al., 2014), as well as creation of iPS cell lines from individuals with mosaic DS (Murray, et al., 2015; Weick, et al., 2013), and the spontaneous reversion to disomy 21 in a DS iPS cell line (Maclean, et al., 2012), provide us with isogenic lines with which to study this disorder. An early paper (2008) demonstrated AD-like deficits in endocytic function in fibroblasts from DS individuals (Cataldo, et al., 2008). In 2012, the Livesey group created iPS cells from one DS patient and one control and examined them for AD-like pathology (Shi, et al., 2012). Interestingly, the DS line secreted far higher levels of both A $\beta$ <sub>40</sub> and A $\beta$ <sub>42</sub> as fibroblasts, than did control cells. Following two months in neuronal culture, aggregates of A $\beta$ <sub>42</sub> were detected in the DS cultures using live staining with the thioflavin T analog, BTA1 and immunocytochemistry against A $\beta$ <sub>42</sub>. A twenty-one day treatment with DAPT nearly abolished both species of A $\beta$  production in the DS neurons. Tau pathology was also evident in neurons differentiated from DS iPS cells, detectable as an abnormal distribution of phospho-tau within the neurons as well as secreted tau in the medium of DS cultures only. Synapse formation did not appear to differ between neurons from DS and control individuals.

Chang *et al* (2015) created neurons from both hES cell and iPS cell lines (Chang, et al., 2015). Similar to Shi *et al*, the authors found increased immunoreactivity for A $\beta$  and phosphorylated tau. Treatment with n-butylidenephthalide (Bdph), an activator of Wnt signaling, delivered via coated nanoparticles, ameliorated AD-like phenotypes in these cultures. Recently, accelerated aging phenotypes were reported in neurons derived from DS iPS cells compared to isogenic controls (Murray, et al., 2015). Unlike previous models, these cells exhibited differences in proliferation and differentiation. Consistent with earlier

reports, the DS iPS cell-derived neurons had increased A $\beta$  immunoreactivity in fixed cultures, but did not appear to differ electrophysiologically from controls. The DS neurons also exhibit mitochondrial dysfunction and increased DNA damage compared to the controls. This last phenotype is particularly interesting, and the failure of neurons to maintain their genomic integrity appears to be a hallmark both of normal aging and of neurodegenerative disease (Dobbin, et al., 2013; Goto, 1997; Hasty, et al., 2003; Kim, et al., 2008; Lovell and Markesbery, 2007; Lu, et al., 2004; Sahin and DePinho, 2010; Wang, et al., 2013). In conclusion, iPS cell-derived neurons from DS individuals may be useful for modeling phenotypes that are similar between AD and aging in DS, as these cells appear to exhibit both amyloid and tau pathology as well as phenotypes such as endosome dysfunction and DNA damage.

## 7. Disadvantages in modeling AD with iPS cells

### 7.1. Aging in iPS cells

Work by several groups has suggested that reprogramming of the iPS cells “re-set” the epigenome, and that other phenotypes associated with cellular aging, such as mitochondrial function and telomere length, are returned to a “juvenile-like” state (Mahmoudi and Brunet, 2012; Miller and Studer, 2014). This raises the question: can we model phenotypes associated with aging in human neural cells (Isobe, et al., 2014)? Transplantation studies of human neuronal progenitor cells (NPCs) into the rodent brain have suggested that the human neural cells mature on a human, rather than a rodent, timeline (Espuny-Camacho, et al., 2013). However, simply allowing iPS cells-derived neural cells to age *in vitro* is impracticable and expensive. Therefore, several groups have begun to explore the possibility of accelerated aging in these model systems. One approach is to derive iPS cells from individual with Hutchinson-Gilford Progeria syndrome (HGPS), which maintain a truncated product of the mutated *LMNA* gene, progerin, which triggers fast aging (Blondel, et al., 2014; Liu, et al., 2011). Liu *et al* found that the deleterious progerin protein was absent in HGPS patient-derived cells in the iPS cell stage (Liu, et al., 2011). However, upon differentiation to smooth muscle cells, the disease phenotype of progerin accumulation, as well as its ageing-associated cellular defects, were recapitulated. In place of using patient cells, progerin can also simply be overexpressed in iPS cells to induce age-related phenotypes such as DNA damage and mitochondrial dysfunction (Miller, et al., 2013). Increases in DNA damage have also been observed in iPS cells derived from individuals with Werner Syndrome, an accelerated aging disorder arising from mutations in the *WRN* gene, which encodes a DNA helicase (Shimamoto, et al., 2015).

Instead of progerin overexpression, other “stimulating” factors might be used, which activate aging pathways. An interesting example has been shown for cardiomyocytes from differentiated iPS cells of patients with arrhythmogenic right ventricular dysplasia. These cells were exposed to a three-factor cocktail, which activates PPAR $\alpha$  and leads to increased fatty acid oxidation instead of glycolysis (Wen, et al., 2015). In this way, the authors recapitulate the adult cardiomyocyte-like metabolism in these cells, which could be pushed to the desired disease pathologies by further treatment with PPAR $\gamma$  activators. Although these techniques appear to induce aging phenotypes in iPS cell derivatives, we first have to

understand the underlying association of aging with AD to incorporate systematic approaches to age neurons.

## 7.2. Neuronal maturation

In all iPS cell approaches, it is necessary to confirm the maturity and the functionality of the derived neurons. While some studies in neurodegenerative disorders use nestin and Pax6-positive NPCs as a kind of proxy to neurons (Hossini, et al., 2015), others have gone to lengths to demonstrate the degree to which iPS cell-derived neurons model *in vivo* human neurons (Israel, et al., 2012). The most common methods to confirm neuronal differentiation and maturity are a combination of immunocytochemistry and electrophysiology (Israel, et al., 2012; Nieweg, et al., 2015): Mature neurons should show the ability to fire action potentials when depolarized under current clamp, as well as demonstrating spontaneous excitatory and inhibitory postsynaptic currents under single-cell patch-clamp. Immunocytochemistry for synaptic vesicle proteins, such as VGLUT1, VAMP2, synaptobrevin, and synapsin, are indicative for mature functional synapses (Marchetto, et al., 2010; Nieweg, et al., 2015). One early screening effort emphasized the need to create mature neuronal cultures for reliable drug assays (Yahata, et al., 2011). Thus, one major challenge to researchers is to provide neuronal cultures that are both mature enough to be representative of adult brain neurons, while being abundant enough for multiple types of assays. Occasionally the presence of disease mutations may hamper efforts to create human neural cell models of disease. For example, neurons created from patient-derived iPS cells carrying FTD mutations in *MAPT* have been shown to mature more quickly than control lines, while at the same time displaying disease phenotypes such as hyperphosphorylated Tau (Iovino, et al., 2015). In contrast, another group using iPS cell-derived neurons carrying the same *MAPT* mutation (N279K) reported that these cells had deficits in neuronal maturation compared to control lines (Wren, et al., 2015). The issue of altered proliferation and/or differentiation of neural progenitor cells and neurons seems particularly troublesome in work with Down syndrome lines (Hibaoui, et al., 2014; Murray, et al., 2015).

## 7.3. Culture heterogeneity and disease phenotypes

Another important aspect is that in several studies it is not obvious to what extent the reported neuronal cultures contain other cell types, nor whether heterogeneous cultures may encourage neuronal differentiation (Sandoe and Eggan, 2013; Shi, et al., 2012; Shi, et al., 2012). While pure cultures of neurons can form synapses and display connectivity, they may not mature fully in the absence of astrocytes or glial-conditioned medium (Pfrieger, 2009; Pfrieger and Barres, 1997; Ullian, et al., 2004). Along these lines, some groups have found that the addition of astrocytes to iPS cell-derived neuronal cultures enhances the ability to obtain mature neurons (Odawara, et al., 2014; Zhang, et al., 2013); this is an area of active debate and constant methodological improvement. Overall, it is necessary to fully characterize the cell type maturity as well as the heterogeneity of neural cultures derived from iPS cells. In this regard, the advent of three-dimensional neural cultures derived from human iPS cells may be particularly beneficial as discussed later.

Finally, a major challenge is to generate a distinct cell type to study its involvement in a disease phenotype. It is hypothesized that only a certain subset of cells fails in many

neurological diseases, for example, a subpopulation of dopaminergic cells in Parkinson's disease (Sandoe and Eggan, 2013). Moreover, the phenotypes displayed by cells bearing physiological mutations, such as familial AD mutations, may often be less robust than those obtained via the experimental overexpression of mutant proteins. One study compared the effect of compound treatment on neural cells from fAD patients to either heterologous cell lines overexpressing fAD *APP*, or human control ES-derived neural cells overexpressing mutant *APP*. They observed that concentrations of indomethacin that reduced  $A\beta_{42/40}$  robustly in the heterologous cells, and more modestly in the APP-overexpressing human cells, had no effect on the human neural cells carrying endogenous fAD mutations (Mertens, et al., 2013). Most researchers who use patient-derived iPS cells carrying familial mutations will be familiar with this issue of comparatively mild disease phenotypes, at least compared to models of gene overexpression or knockdown. Fortunately, the use of isogenic lines with corrected disease alleles may, by reducing variability between lines, allow for the reliable measurement of even modest phenotypes. The increased use of three-dimensional tissue culture systems (see Section 8), may also facilitate disease phenotypes by concentrating protein aggregates and other cellular products in a tissue-like environment that can still be imaged or assayed with ease.

In addition to the issue of variability between iPS cell-derived lines in assays of disease phenotypes, we are faced with the growing awareness that other cell types must be created to model AD in these systems. For example, in the last decade, it has become obvious that glia cells have an important impact in disease onset and progression. Thus, our basic science interests demand that we increase the complexity of our cellular models to adequately represent the disease, while at the same time we are tasked with the production of simplified systems that are amenable to applications such as drug screening.

## 8. Differentiation of iPS cells to study cell type-specific impact toward neurological diseases

Generation of iPS cells typically serves as a starting point to differentiate them into various brain-specific cell types such as neurons or glial cells. Each cell lineage develops, when a combination of exogenous morphogens are applied at distinct time points during development of the iPS cells (Liu and Zhang, 2011). An alternative strategy is the overexpression of cell type-specific transcription factors (B. Zhang et al., 2013; Y. Zhang et al., 2013). In the following, we focus on examples of the successful generation of neuronal and glial cell types from human iPS cells.

### 8.1. Differentiation to distinct neuronal cell types

The initial iPS cell study by Takahashi *et al.* demonstrated the successful generation of neuronal cells from iPS cells (Takahashi, et al., 2007). It is now common to perform neuronal differentiation (Denham and Dottori, 2011), and even to differentiate into specific neuronal subtypes, such as forebrain glutamatergic neurons (Zeng, et al., 2010), cortical neurons (Nieweg, et al., 2015; Shi, et al., 2012), GABAergic interneurons (Liu, et al., 2013; Nieweg, et al., 2015), motor neurons (Ebert, et al., 2009), and hypothalamic-like neurons (Wang, et al., 2015). Indeed, there are too many neuronal differentiation techniques in the

literature to adequately review here (some recent reviews include (Broccoli, et al., 2015; Broccoli, et al., 2014; Chinchalongporn, et al., 2015; Lai, et al., 2015)). The generation of inhibitory neurons is of particular interest for AD research, since both inhibitory and excitatory neurons are affected (Hazra, et al., 2013; Krantic, et al., 2012), and inhibitory interneurons, such as parvalbuminergic cells, play crucial roles in orchestrating large networks crucial to memory formation (Bartos, et al., 2007; Mann and Paulsen, 2007). The development of protocols for the differentiation of multiple neural subtypes is a lively area of research.

## 8.2. Differentiation to glia

In the brain, glial cells can be divided in three major cell classes: astrocytes, microglia, and oligodendrocytes. Each of them has been proposed to have an important impact in AD's onset and progression; even so it is still debatable, whether they are causative for the disease or just represent a secondary by-standing effect. Overall human AD and mouse gene expression studies show that with AD progression, immune response and inflammatory genes are up- and genes involved in neuronal functions are down-regulated (Blalock, et al., 2011; Blalock, et al., 2004; Gjoneska, et al., 2015). Interestingly, GWAS describe several AD-risk increasing genetic variants, which are linked to genes with identified roles in glial cells, such as *APOE*, *PICALM*, *TREM2*, *CRI*, *CD33* and *CLU* (Ando, et al., 2013; Antunez, et al., 2011; Bertram, et al., 2008; Bradshaw, et al., 2013; Calero, et al., 2000; Corneveaux, et al., 2010; Crehan, et al., 2013; Deng, et al., 2012; Guerreiro, et al., 2013; Harold, et al., 2009; Hollingworth, et al., 2011; Jonsson, et al., 2013; Lambert, et al., 2009; Lambert, et al., 2010; Wunderlich, et al., 2013; Zhang, et al., 2010). Apolipoprotein *APOE* was originally identified in the liver that mediates the transport and delivery of cholesterol and other lipids through cell surface ApoE receptors (Mahley, 1988; Mahley and Rall, 2000). The human *APOE* gene exists as three alleles. While these three variants have a frequency in the population of 8.4% ( $\epsilon 2$ ), 77.9% ( $\epsilon 3$ ), and 13.7% ( $\epsilon 4$ ), the frequency of the *APOE*  $\epsilon 4$  variant (*APOE4*) is increased to at least 40% in sporadic AD patients (Farrer, et al., 1997) making it as one of the greatest risk factors for sAD (Kanekiyo, et al., 2014; Lambert, et al., 2013). Individuals with one *APOE4* allele are three to four times as likely to develop AD than those without *APOE4* alleles, an odds ratio that is by far the highest out of any AD risk gene (Bertram and Tanzi, 2008; Corder, et al., 1993). In both humans and in animal models, the *APOE4* allele is associated with increased levels of amyloid beta ( $A\beta$ ), as well as amyloid plaque deposition (Castellano, et al., 2011; Fryer, et al., 2005; Kim, et al., 2009; Youmans, et al., 2012). The least common variant, *APOE2*, differs from the *APOE4* variant at just two amino acid positions but appears to be protective against the development of AD (Bu, 2009; Corder, et al., 1993; Liu, et al., 2013). While the contribution of the *APOE4* allele to AD risk is well known, the reasons *why* this variant may trigger AD are not at all understood. The study of these *APOE* variants has been particularly difficult in rodent models, which endogenously express only one version of the *ApoE* gene. Thus, the emergence of iPS cell lines with different *APOE* isotypes will greatly advance our understanding of this AD risk factor by either collecting individuals of particular genotypes, or by using genome editing to “switch” between the protective and the disease-causing *APOE* form within the same genotype.

Taken together, two important themes emerge from these observations: 1) neurodegeneration in AD most likely involves an interaction of neuronal and glial pathologies; and 2) understanding the functions of genes implicated in AD, from GWAS or expression studies, will require a thorough characterization of their functions in a cell type-specific manner. Since human and mouse glia are surprisingly divergent (Oberheim, et al., 2006; Oberheim, et al., 2009), which places emphasis on the need for models of human glia for the study of neurodegenerative disease.

**8.2.1. Astrocytes**—Astrocytes are a diverse cell class, which can differ both functionally and morphologically between brain regions (Bribian, et al., 2015; Ma, et al., 1999; Tabata, 2015) as well as displaying significant species divergence (Oberheim, et al., 2006; Oberheim, et al., 2009). Astrocytes are intimately involved in synaptogenesis and synapse maintenance (Haydon and Nedergaard, 2015; Pascual, et al., 2005; Perea, et al., 2009), maintain brain homeostasis, store and distribute energy substrates, and play a major role in the clearance of metabolites and toxins from the brain parenchyma (Jessen, et al., 2015; Xie, et al., 2013). Inflammatory astrogliosis precede or accompany neurodegeneration in many animal models and human postmortem AD brains, as evidenced by increased immunoreactivity for glial fibrillary acidic protein (GFAP) as well as by the loss of important astrocytic proteins such as glutamine synthase and GLT-1 (Dabir, et al., 2006; Fischer, et al., 2005; Li, et al., 1997; Masliah, et al., 2000; Robinson, 2001; Tilleux and Hermans, 2007). Moreover, astrocytes in the brain are the primary producer of the ApoE protein under physiological conditions, although cell profiling studies have implicated microglia as another prominent ApoE source (F. Zhang et al., 2014; Y. Zhang et al., 2014; D. Zhang et al., 2014).

While differentiation from iPS cells focused initially on creating functional human neurons, several groups have now also developed protocols to differentiate astrocytes from iPS cells. In spontaneously differentiating cultures, astrocytes will appear roughly 100 days from the time that neural progenitor cells are placed in differentiation media (Shi et al., 2012a, 2012b, 2012c). To obtain faster cultures with a higher purity of astrocytes, techniques have been developed to obtain astrocytes from gliospheres (Krencik, et al., 2011) or by directed differentiation via defined factors (Chen, et al., 2014). Astrocyte-like cells can also be obtained via direct reprogramming of fibroblast cells (Caiazzo, et al., 2015). The admirable plasticity of these glial cells, however, which make them such an important and adaptable cell in the brain, has historically led to issues of how representative primary cultured astrocytes are compared to the *in vivo* situation (Foo, et al., 2011; Hertz, et al., 1998; Sun, et al., 2013). Given the different protocols in development to create iPS cell-derived human astroglia, the issue of variability between different groups and different cell lines is likely to require a concerted effort by the entire neural iPS cell community to address this issue.

**8.2.2. Microglia**—Microglia are complex and dynamic cells responding to their environment by releasing chemical transmitters as well as phagocytize cell debris, synapses, or whole cells. Both pro-inflammatory and neuroprotective roles for microglia have been demonstrated in AD. Local resident microglia become activated and rapidly react to amyloid plaque formation by extending processes, migrating toward plaques, and aggregate around



them (Bolmont, et al., 2008; Lue, et al., 2001). Also, microglia are demonstrated to undergo apoptosis in AD brain (Lassmann, et al., 1995; Sugaya, et al., 1997; Yang, et al., 1998) and show dystrophic morphology and fragmentation, which could be the reason of the senescence of these cells (Streit, et al., 2009; Streit and Xue, 2010).

The differentiation of microglia from iPS cells appears possible, though perhaps more challenging than other neural cell types, given the unique origin of microglia (Ginhoux, et al., 2010). To date, however, while publications exist for creating mouse microglia (Beutner et al., 2010; Beutner et al., 2013; Selvaraj et al., 2012; Tsuchiya et al., 2005), resources describing human iPS cell-derived microglia are rare. We found one patent related to the “Method for obtaining human microglial precursor cells from pluripotent stem cells” (EP 2424976 A1) from the group of Harald Neumann (Neumann, 2012), who also have derived microglial cells from mouse ES cells (Beutner, et al., 2010; Beutner, et al., 2013). Another strategy was introduced by the Filgueira group, who generated microglia from human peripheral blood monocytes using a mixture of recombinant cytokines such as M-CSF, GM-CSF, NGF $\beta$ , and CCL2 (Etemad, et al., 2012). A report that focuses on the analysis of FTD phenotypes in iPS cell-derived neurons mentions the creation of Iba1-positive cells from embryoid bodies, but does not further characterize these cells (Almeida et al., 2012). Some groups have found that, in the process of making embryoid bodies and three-dimensional cultures, that they are able to isolate Cd11b+/CD45+ monocyte-like cells (Schwartz, et al., 2015). However, whether these microglial precursors are representing the same characteristic as the microglia *in vivo* is a matter of debate, and our understanding of microglia and their roles in Alzheimer’s disease remains woefully incomplete. To date, we could not find any work in the literature that focused upon creating microglia from human ES or iPS cells. The production of microglia from human iPS cells is highly desirable, given our increasing awareness of the role of inflammation in neurodegenerative disease, and we look forward to seeing new protocols in the literature soon.

**8.2.3. Oligodendrocytes**—Oligodendrocytes form myelin layers around neuronal axons in order to allow high nerve conductance (Bercury and Macklin, 2015). White matter lesions and myelin abnormalities have been described in human AD brain and mouse models (Bartzokis, 2011; Desai, et al., 2010; Desai, et al., 2009; Englund, et al., 1988; Kobayashi, et al., 2002; Roth, et al., 2005). The potential that iPS cell-derived oligodendrocyte precursor cells and mature oligodendrocytes have for both the study and treatment of demyelinating disorders has made this an active field, with a number of groups developing protocols. These studies have generated oligodendrocytes and oligodendrocytes precursors from human iPS cells either as a component of heterogeneous cultures (Hu, et al., 2009; Kim, et al., 2012; Swistowski, et al., 2010) or as the result of concerted efforts to generate these particular cell types (Douvaras, et al., 2014; Jang, et al., 2011; Ogawa, et al., 2011; Pouya, et al., 2011; Wang, et al., 2013). Oligodendrocytes derived from human iPS cells have been shown to myelinate neuronal processes *in vitro* (S. Wang et al., 2013; X.Y. Wang et al., 2013) and *in vivo* (Douvaras et al., 2014; Major et al., 2011; Pouya et al., 2011; S. Wang et al., 2013; X.Y. Wang et al., 2013), and thus hold great promise for studying the impact of myelin abnormalities in AD and other demyelinating disorders.

### 8.3. Future challenges for cell type differentiation

For each cell type differentiation, it will be crucial to eliminate remaining pluripotent iPS as well as progenitor cells. There are several options such as fluorescent-activated cell sorting (Sergent-Tanguy, et al., 2003) or magnetic separation, however they are very invasive and could potentially change the epigenetic landscape. It would be from advantage to have a marker of successful differentiation. (Kim, et al., 2011) showed that the microRNA-371-3 cluster could serve as a discrimination factor for neuronal differentiation.

One major challenge will be to define what is a cell type and which cell type is impacted in a disease phenotype. To define a cell type is challenging by itself (DeFelipe, et al., 2013; Fishell and Heintz, 2013; Grange, et al., 2014) but solving this question will be crucial for future studies in iPS cells. This requires that we understand the genetic identity of a cell type, so that we can investigate strategies to specifically promote this cell type to differentiate from iPS cells. Once we know the genetic identity of a natural cell, we can correlate this identity to our engineered cell *in vitro*. Strategies like this are already proposed within the retina (Siebert, et al., 2012).

## 9. Modeling neurological disease in three-dimensional culture systems

In the previous section, we briefly alluded to the impact of distinct cell types in AD and what are the current efforts in the field to generate these different neural lineages from iPS cells. Although the analysis of a pure cell type population can give valuable insides into the biology of the cell, it is often the interaction between different cell types that are most important to a true model of neural systems: for example neurons exhibit increased synapse formation when they are co-cultured with astrocytes (Pfrieger and Barres, 1997), and astrocytes may look and behave differently in two-dimensional culture than they do in the brain (Cahoy, et al., 2008; Puschmann, et al., 2013). The latter one is a concern for all cell types, since neurons and glia both utilize subcellular specializations, or compartmentalization, to function properly *in vivo* (Khakh and McCarthy, 2015; Tonnesen, et al., 2014). In a monolayer in a culture dish, however, some of this compartmentalization may be lost. One example is the observation of calcium microdomains in astrocytes *in vivo* and in slice preparations, in which specific subregions of the astrocytic arbor exhibit restricted calcium oscillations that may reflect activity to immediately adjacent neurons (Bernardinelli, et al., 2014; Di Castro, et al., 2011; Shigetomi, et al., 2013). Another concern is that phenotypes of aberrant extracellular protein aggregation are lost in two-dimensional cultures simply due to the lack of interstitial compartment, and metabolites of interest may diffuse to the media. To overcome this, recent studies have embedded human ES or iPS cell-derived cells in scaffolding such as hydrogel or Matrigel, to create three dimensional culture systems (Pasca, et al., 2015; Schwartz, et al., 2015; Smith, et al., 2015). These kinds of culture systems, when created with human cells overexpressing fAD proteins or treated with A $\beta$  oligomers, can recapitulate AD-like phenotypes such as extracellular A $\beta$  plaque-like deposits (Choi et al., 2014; Kim et al., 2015) and cytoskeletal abnormalities (F. Zhang et al., 2014; Y. Zhang et al., 2014; D. Zhang et al., 2014).

To address issues that might arise from overly simplistic culture model systems, a number of groups have taken advantage of tissue engineering approaches that can generate either

scaffolded or self-organizing neural cytosystems, such as “organoids”. In 2008, the Sasai laboratory demonstrated that mouse and human ES cells could form self-organized apico-basally polarized cortical tissue (Eiraku and Sasai, 2012; Eiraku, et al., 2008). However this technique lacks the later stage of cortical development namely discrete cortical layer formation with the typically inside-out organization, as well as the presence of outer radial glia. (Lancaster, et al., 2013) improved the protocol and could model human brain development in 3D organoid structure. They observed cortical-like neuronal generation and organization and found astrocytes and oligodendrocytes after more than 100 days *in vitro*. To date, AD-like phenotypes have not been reported in self-organizing three-dimensional cultures or organoids from patient-derived cells. However, the three-dimensional cultures reported by Choi *et al.*, which overexpressed mutant APP, also showed an increase in phospho-Tau levels, suggesting that it may be possible to recapitulate many AD phenotypes within one model system, which would be a strong advantage in comparison to AD mouse models (Choi, et al., 2014; Kim, et al., 2015). Three-dimensional neural culture systems have yet to recapitulate complex *in vivo* brain systems that include elements such as the blood-brain-barrier, vascularization, or immune response, which all have an important impact during disease and treatment. Therefore, multiple research groups are focusing on creating vascularization, shown in liver tissue (Masumoto, et al., 2014; Samuel, et al., 2013; Takebe, et al., 2013) or blood-brain-barrier structures from iPS cells (Lippmann, et al., 2014; Lippmann, et al., 2013; Lippmann, et al., 2012; Minami, et al., 2015).

## 10. Conclusion

In this review, we have outlined recent strategies to investigate AD pathology using human iPS cells and to find new therapeutic targets preventing disease onset and progression. The approval rate for AD medications is a scant 4% of all treatments that enter onto Phase I trials (McBride, 2012) with projections of 13.8 million people with AD and \$1.2 trillion spent on AD-related care in the year 2050 (Association, 2013; Hebert, et al., 2013). These numbers clearly show that new model systems are needed to better translate observations from rodent models into clinical studies. Human iPS cells will be an important step forward in this direction; they have the potential to recapitulate phenotypes from various neurological diseases in a cell type-specific manner. Creating isogenic iPS cells lines overcomes problems of variability in human genomes and genome-editing technology has become much easier to implement. We have outlined how iPS cells can model disease etiology, progression, and phenotypes in human AD. Several groups have, to date, succeeded in recapitulating multiple AD-like phenotypes in human iPS cells. Thus, the stage appears to be set for the widespread use of iPS cells in preclinical drug trials for AD therapies (reviewed in (Khurana, et al., 2015)). To benefit most from these cellular models, it will be absolutely crucial that all experiments are performed in a controlled and standardized manner that will allow reproducibility between different research groups.

Several areas of iPS cell research remain topics of much debate or even controversy. For example, there is debate over exactly how similar iPS and ES cells are, and how well iPS cells can functionally replace ES cells in translational research (Bock et al., 2011; Chin et al., 2009; Doi et al., 2009; Hu et al., 2010; Narsinh et al., 2011a, 2011b). In addition to the ethical and legal issues that have arisen regarding the creation of ES cells, which hinder the

production of new lines, a clear advantage of iPS cells is that the donor is often an adult, sometimes elderly, and thus can provide a health history relevant to the disorder of interest. This is not possible with ES cells. This said, the ability to access patient history in the use of iPS cell research is highly variable between research groups and subject to a great deal of regulation to ensure patient privacy (King and Perrin, 2014; Lomax, et al., 2015; Lomax and Peckman, 2012; Lomax, et al., 2013). As more and more iPS cell lines are characterized and this information added to public databases, we expect that even researchers without direct access to patient information will benefit from these models. The development of libraries of disease-associated iPS cell lines, of both genders, will allow high-throughput drug discovery and validation, and should make the rocky path from bench to clinic shorter and straighter.

In this review, we also put a strong focus on the impact of different cell types. It will be crucial to investigate the impact of drugs across different cell types. The use of three-dimensional scaffolding combined with differentiated cells (Choi, et al., 2014), or the creation of self-organizing neural tissue structures *in vitro* (Eiraku and Sasai, 2012; Eiraku, et al., 2008; Kadoshima, et al., 2013; Lancaster, et al., 2013; Lancaster and Knoblich, 2014), hold great promise for modeling the intricate micro- and macro-environment of the brain. In the future, it may be possible to screen drugs in these cytosystems, which have the benefit of containing multiple neural cell types in a physiological microenvironment and, with the development of vascularization technique, may include blood-brain barrier penetration in the assay at an early stage of drug discovery.

## Acknowledgments

This work was supported by NIH grant R01-AG047661 to LHT. The art in Fig. 1 was created by Julian Wong.

## References

- Strengthening connections between Down syndrome and AD. *Lancet Neurol.* 2013; 12:931. PMID: 24050729. doi: 10.1016/S1474-4422(13)70228-X [PubMed: 24050729]
- Almeida S, Zhang Z, Coppola G, Mao W, Futai K, Karydas A, Geschwind MD, Tartaglia MC, Gao F, Gianni D, Sena-Esteves M, Geschwind DH, Miller BL, Farese RV Jr, Gao FB. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. *Cell Rep.* 2012; 2:789–798. <http://dx.doi.org/10.1016/j.celrep.2012.09.007>. [PubMed: 23063362]
- Alzheimer A. Über eigenartige Krankheitsfalle des späteren Alters. *Zbl. ges. Neurol. Psych.* 1911; 4:356–385.
- Ando K, Brion JP, Stygelbout V, Suain V, Authelet M, Dedecker R, Chanut A, Lacor P, Lavour J, Sazdovitch V, Rogueva E, Potier MC, Duyckaerts C. Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer's brains. *Acta Neuropathol.* 2013; 125:861–78. PMID: 23589030. DOI: 10.1007/s00401-013-1111-z [PubMed: 23589030]
- Antunez C, Boada M, Gonzalez-Perez A, Gayan J, Ramirez-Lorca R, Marin J, Hernandez I, Moreno-Rey C, Moron FJ, Lopez-Arrieta J, Mauleon A, Rosende-Roca M, Noguera-Perea F, Legaz-Garcia A, Vivancos-Moreau L, Velasco J, Carrasco JM, Alegret M, Antequera-Torres M, Manzanares S, Romo A, Blanca I, Ruiz S, Espinosa A, Castano S, Garcia B, Martinez-Herrada B, Vinyes G, Lafuente A, Becker JT, Galan JJ, Serrano-Rios M, Alzheimer's Disease Neuroimaging I, Vazquez E, Tarraga L, Saez ME, Lopez OL, Real LM, Ruiz A. The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer's disease. *Genome Med.* 2011; 3:33. PMID: 21627779. doi: 10.1186/gm249 [PubMed: 21627779]

- Association A. 2013 Alzheimer's disease facts and figures. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2013; 8:131–68. PMID: 22404854. DOI: 10.1016/j.jalz.2012.02.001
- Ballatore C, Lee VMY, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. *Nature Reviews Neuroscience*. 2007; 8:663–672. [PubMed: 17684513]
- Bartos M, Vida I, Jonas P. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. *Nat Rev Neurosci*. 2007; 8:45–56. PMID: 17180162. DOI: 10.1038/nrn2044 [PubMed: 17180162]
- Bartzokis G. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. *Neurobiol Aging*. 2011; 32:1341–71. PMID: 19775776. DOI: 10.1016/j.neurobiolaging.2009.08.007 [PubMed: 19775776]
- Bercury KK, Macklin WB. Dynamics and mechanisms of CNS myelination. *Dev Cell*. 2015; 32:447–58. PMID: 25710531. DOI: 10.1016/j.devcel.2015.01.016 [PubMed: 25710531]
- Bernardinelli Y, Randall J, Janett E, Nikonenko I, Konig S, Jones EV, Flores CE, Murai KK, Bochet CG, Holtmaat A, Muller D. Activity-dependent structural plasticity of perisynaptic astrocytic domains promotes excitatory synapse stability. *Curr Biol*. 2014; 24:1679–88. PMID: 25042585. DOI: 10.1016/j.cub.2014.06.025 [PubMed: 25042585]
- Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BM, Hooli B, Divito J, Ionita I, Jiang H, Laird N, Moscarillo T, Ohlsen KL, Elliott K, Wang X, Hu-Lince D, Ryder M, Murphy A, Wagner SL, Blacker D, Becker KD, Tanzi RE. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. *Am J Hum Genet*. 2008; 83:623–32. PMID: 18976728. DOI: 10.1016/j.ajhg.2008.10.008 [PubMed: 18976728]
- Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. *Nat Genet*. 2007; 39:17–23. PMID: 17192785. DOI: 10.1038/ng1934 [PubMed: 17192785]
- Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: The implications of systematic meta-analyses. *Nature Reviews Neuroscience*. 2008; 9:768–778. [PubMed: 18802446]
- Beutner C, Roy K, Linnartz B, Napoli I, Neumann H. Generation of microglial cells from mouse embryonic stem cells. *Nat Protoc*. 2010; 5:1481–94. PMID: 20725065. DOI: 10.1038/nprot.2010.90 [PubMed: 20725065]
- Beutner C, Linnartz-Gerlach B, Schmidt SV, Beyer M, Mallmann MR, Staratschek-Jox A, Schultze JL, Neumann H. Unique transcriptome signature of mouse microglia. *Glia*. 2013; 61:1429–42. PMID: 23832717. DOI: 10.1002/glia.22524 [PubMed: 23832717]
- Beyreuther K, Pollwein P, Multhaup G, Monning U, Konig G, Dyrks T, Schubert W, Masters CL. Regulation and expression of the Alzheimer's beta/A4 amyloid protein precursor in health, disease, and Down's syndrome. *Ann N Y Acad Sci*. 1993; 695:91–102. PMID: 8239320. [PubMed: 8239320]
- Biancotti JC, Narwani K, Buehler N, Mandefro B, Golan-Lev T, Yanuka O, Clark A, Hill D, Benvenisty N, Lavon N. Human embryonic stem cells as models for aneuploid chromosomal syndromes. *Stem Cells*. 2010; 28:1530–1540. (20641042). [PubMed: 20641042]
- Blalock EM, Buechel HM, Popovic J, Geddes JW, Landfield PW. Microarray analyses of laser-captured hippocampus reveal distinct gray and white matter signatures associated with incipient Alzheimer's disease. *Journal of chemical neuroanatomy*. 2011; 42:118–26. PMID: 21756998. DOI: 10.1016/j.jchemneu.2011.06.007 [PubMed: 21756998]
- Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. *Proc Natl Acad Sci U S A*. 2004; 101:2173–8. PMID: 14769913. DOI: 10.1073/pnas.0308512100 [PubMed: 14769913]
- Blennow K. Biomarkers in Alzheimer's disease drug development. *Nat Med*. 2010; 16:1218–22. PMID: 21052077. DOI: 10.1038/nm.2221 [PubMed: 21052077]
- Blondel S, Jaskowiak AL, Egesipe AL, Le Corf A, Navarro C, Cordette V, Martinat C, Laabi Y, Djabali K, de Sandre-Giovannoli A, Levy N, Peschanski M, Nissan X. Induced pluripotent stem cells reveal functional differences between drugs currently investigated in patients with hutchinson-gilford progeria syndrome. *Stem Cells Transl Med*. 2014; 3:510–9. PMID: 24598781. DOI: 10.5966/sctm.2013-0168 [PubMed: 24598781]



- Bock C, Kiskinis E, Verstappen G, Gu H, Boulting G, Smith ZD, Ziller M, Croft GF, Amoroso MW, Oakley DH, Gnirke A, Eggen K, Meissner A. Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. *Cell*. 2011; 144:439–52. PMID: 21295703. DOI: 10.1016/j.cell.2010.12.032 [PubMed: 21295703]
- Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. *Journal of Neuroscience*. 2008; 28:4283–4292. PMID: 18417708. DOI: 10.1523/jneurosci.4814-07.2008 [PubMed: 18417708]
- Boulting GL, Kiskinis E, Croft GF, Amoroso MW, Oakley DH, Wainger BJ, Williams DJ, Kahler DJ, Yamaki M, Davidow L, Rodolfa CT, Dimos JT, Mikkilineni S, MacDermott AB, Woolf CJ, Henderson CE, Wichterle H, Eggen K. A functionally characterized test set of human induced pluripotent stem cells. *Nature Biotechnology*. 2011; 29:279–U147. PMID: 21293464. DOI: 10.1038/nbt.1783
- Bouwman BA, de Laat W. Architectural hallmarks of the pluripotent genome. *FEBS Lett*. 2015; PMID: 25957773. doi: 10.1016/j.febslet.2015.04.055
- Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*. 1991; 82:239–59. PMID: 1759558. [PubMed: 1759558]
- Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboya S, Lee M, Von Korff A, Morris MC, Evans DA, Johnson K, Sperling RA, Schneider JA, Bennett DA, De Jager PL. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. *Nature Neuroscience*. 2013; 16:848–850. doi: papers2://publication/doi/10.1038/nn.3435. [PubMed: 23708142]
- Brennan KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, Li Y, Mu Y, Chen G, Yu D, McCarthy S, Sebat J, Gage FH. Modelling schizophrenia using human induced pluripotent stem cells. *Nature*. 2011; 473:221. PMID: 21490598. doi: 10.1038/nature09915 [PubMed: 21490598]
- Bribian A, Figueres-Onate M, Martin-Lopez E, Lopez-Mascaraque L. Decoding astrocyte heterogeneity: New tools for clonal analysis. *Neuroscience*. 2015; PMID: 25917835. doi: 10.1016/j.neuroscience.2015.04.036
- Broccoli V, Rubio A, Taverna S, Yekhelef L. Overcoming the hurdles for a reproducible generation of human functionally mature reprogrammed neurons. *Exp Biol Med (Maywood)*. 2015; 240:787–94. PMID: 25790823. DOI: 10.1177/1535370215577585 [PubMed: 25790823]
- Broccoli V, Giannelli SG, Mazzara PG. Modeling physiological and pathological human neurogenesis in the dish. *Front Neurosci*. 2014; 8:183. PMID: 25104921. doi: 10.3389/fnins.2014.00183 [PubMed: 25104921]
- Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. *Nat Rev Neurosci*. 2009; 10:333–44. PMID: 19339974. DOI: 10.1038/nrn2620 [PubMed: 19339974]
- Burger PC, Vogel FS. The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. *Am J Pathol*. 1973; 73:457–76. PMID: 4271339. [PubMed: 4271339]
- Byrne SM, Mali P, Church GM. Genome editing in human stem cells. *Methods Enzymol*. 2014; 546:119–38. PMID: 25398338. DOI: 10.1016/B978-0-12-801185-0.00006-4 [PubMed: 25398338]
- Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, Lubischer JL, Krieg PA, Krupenko SA, Thompson WJ, Barres BA. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. *J Neurosci*. 2008; 28:264–78. PMID: 18171944. DOI: 10.1523/JNEUROSCI.4178-07.2008 [PubMed: 18171944]
- Caiazzo M, Giannelli S, Valente P, Lignani G, Carissimo A, Sessa A, Colasante G, Bartolomeo R, Massimino L, Ferroni S, Settembre C, Benfenati F, Broccoli V. Direct conversion of fibroblasts into functional astrocytes by defined transcription factors. *Stem Cell Reports*. 2015; 4:25–36. PMID: 25556566. DOI: 10.1016/j.stemcr.2014.12.002 [PubMed: 25556566]
- Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. *Microsc Res Tech*. 2000; 50:305–15. PMID: 10936885. DOI: 10.1002/1097-0029(20000815)50:4<305::AID-JEMT10>3.0.CO;2-L [PubMed: 10936885]



- Carroll D. Genome Engineering With Zinc-Finger Nucleases. *Genetics*. 2011; 188:773–782. PMID: 21828278. DOI: 10.1534/genetics.111.131433 [PubMed: 21828278]
- Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. Human apoE isoforms differentially regulate brain amyloid- $\beta$  peptide clearance. *Science Translational Medicine*. 2011;3.
- Cataldo A, Rebeck GW, Ghetti B, Hulette C, Lippa C, Van Broeckhoven C, van Duijn C, Cras P, Bogdanovic N, Bird T, Peterhoff C, Nixon R. Endocytic disturbances distinguish among subtypes of Alzheimer's disease and related disorders. *Ann Neurol*. 2001; 50:661–5. PMID: 11706973. [PubMed: 11706973]
- Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid  $\beta$  deposition in sporadic Alzheimer's disease and Down syndrome: Differential effects of APOE genotype and presenilin mutations. *American Journal Of Pathology*. 2000; 157:277–286. [PubMed: 10880397]
- Cataldo AM, Mathews PM, Boiteau AB, Hassinger LC, Peterhoff CM, Jiang Y, Mullaney K, Neve RL, Gruenberg J, Nixon RA. Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. *Am J Pathol*. 2008; 173:370–84. PMID: 18535180. DOI: 10.2353/ajpath.2008.071053 [PubMed: 18535180]
- Chang CY, Chen SM, Lu HE, Lai SM, Lai PS, Shen PW, Chen PY, Shen CI, Harn HJ, Lin SZ, Hwang SM, Su HL. N-butylidenephthalide Attenuates Alzheimer's Disease-Like Cytotoxicity in Down Syndrome Induced Pluripotent Stem Cell-Derived Neurons. *Sci Rep*. 2015; 5:8744. PMID: 25735452. doi: 10.1038/srep08744 [PubMed: 25735452]
- Chen C, Jiang P, Xue H, Peterson SE, Tran HT, McCann AE, Parast MM, Li S, Pleasure DE, Laurent LC, Loring JF, Liu Y, Deng W. Role of astroglia in Down's syndrome revealed by patient-derived human-induced pluripotent stem cells. *Nat Commun*. 2014; 5:4430. PMID: 25034944. doi: 10.1038/ncomms5430 [PubMed: 25034944]
- Chiba K, Hockemeyer D. Genome Editing in Human Pluripotent Stem Cells Using Site-Specific Nucleases. *Chromosomal Mutagenesis, Second Edition*. 2015; 1239:267–280. PMID: 25408412. DOI: 10.1007/978-1-4939-1862-1\_15
- Chin MH, Mason MJ, Xie W, Volinia S, Singer M, Peterson C, Ambartsumyan G, Aimiwu O, Richter L, Zhang J, Khvorostov I, Ott V, Grunstein M, Lavon N, Benvenisty N, Croce CM, Clark AT, Baxter T, Pyle AD, Teitell MA, Pelegri M, Plath K, Lowry WE. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. *Cell Stem Cell*. 2009; 5:111–23. doi: S1934-5909(09)00292-6 [pii] 10.1016/j.stem.2009.06.008. PMID: 19570518. [PubMed: 19570518]
- Chinchalongporn V, Koppensteiner P, Pre D, Thangnipon W, Biló L, Arancio O. Connectivity and circuitry in a dish versus in a brain. *Alzheimers Res Ther*. 2015; 7:44. PMID: 26045718. doi: 10.1186/s13195-015-0129-y [PubMed: 26045718]
- Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D'Avanzo C, Chen H, Hooli B, Asselin C, Muffat J, Klee JB, Zhang C, Wainger BJ, Peitz M, Kovacs DM, Woolf CJ, Wagner SL, Tanzi RE, Kim DY. A three-dimensional human neural cell culture model of Alzheimer's disease. *Nature*. 2014; 515:274–8. PMID: 25307057. DOI: 10.1038/nature13800 [PubMed: 25307057]
- Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, Mungenast AE, Muffat J, Mitalipova M, Pluth MD, Jui NT, Schule B, Lippard SJ, Tsai LH, Krainc D, Buchwald SL, Jaenisch R, Lindquist S. Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. *Science*. 2013; 342:983–7. PMID: 24158904. DOI: 10.1126/science.1245296 [PubMed: 24158904]
- Consortium HDI. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. *Cell Stem Cell*. 2012; 11:264–78. PMID: 22748968. DOI: 10.1016/j.stem.2012.04.027 [PubMed: 22748968]
- Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science*. 1993; 261:921–923. [PubMed: 8346443]
- Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A, Nalls MA, Chen K, Lee W, Chewning K, Villa SE, Meechoovet HB, Gerber JD, Frost D, Benson HL, O'Reilly S, Chibnik LB,

Shulman JM, Singleton AB, Craig DW, Van Keuren-Jensen KR, Dunckley T, Bennett DA, De Jager PL, Heward C, Hardy J, Reiman EM, Huentelman MJ. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. *Hum Mol Genet.* 2010; 19:3295–301. PMID: 20534741. DOI: 10.1093/hmg/ddq221 [PubMed: 20534741]

Cowan CA, Atienza J, Melton DA, Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. *Science.* 2005; 309:1369–1373. PMID: 16123299. DOI: 10.1126/science.1116447 [PubMed: 16123299]

Crehan H, Hardy J, Pocock J. Blockage of CR1 prevents activation of rodent microglia. *Neurobiol Dis.* 2013; 54:139–49. PMID: 23454195. DOI: 10.1016/j.nbd.2013.02.003 [PubMed: 23454195]

Dabir DV, Robinson MB, Swanson E, Zhang B, Trojanowski JQ, Lee VM, Forman MS. Impaired glutamate transport in a mouse model of tau pathology in astrocytes. *J Neurosci.* 2006; 26:644–54. PMID: 16407562. DOI: 10.1523/JNEUROSCI.3861-05.2006 [PubMed: 16407562]

De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. *Physiol Rev.* 2010; 90:465–94. PMID: 20393191. DOI: 10.1152/physrev.00023.2009 [PubMed: 20393191]

DeFelipe J, Lopez-Cruz PL, Benavides-Piccione R, Bielza C, Larranaga P, Anderson S, Burkhalter A, Cauli B, Fairen A, Feldmeyer D, Fishell G, Fitzpatrick D, Freund TF, Gonzalez-Burgos G, Hestrin S, Hill S, Hof PR, Huang J, Jones EG, Kawaguchi Y, Kisvarday Z, Kubota Y, Lewis DA, Marin O, Markram H, McBain CJ, Meyer HS, Monyer H, Nelson SB, Rockland K, Rossier J, Rubenstein JLR, Rudy B, Scanziani M, Shepherd GM, Sherwood CC, Staiger JF, Tamas G, Thomson A, Wang Y, Yuste R, Ascoli GA. New insights into the classification and nomenclature of cortical GABAergic interneurons. *Nature Reviews Neuroscience.* 2013; 14:202–216. PMID: 23385869. DOI: 10.1038/nrn3444 [PubMed: 23385869]

Deng YL, Liu LH, Wang Y, Tang HD, Ren RJ, Xu W, Ma JF, Wang LL, Zhuang JP, Wang G, Chen SD. The prevalence of CD33 and MS4A6A variant in Chinese Han population with Alzheimer's disease. *Hum Genet.* 2012; 131:1245–9. PMID: 22382309. DOI: 10.1007/s00439-012-1154-6 [PubMed: 22382309]

Denham M, Dottori M. Neural Differentiation of Induced Pluripotent Stem Cells. *Neurodegeneration: Methods and Protocols.* 2011; 793:99–110. PMID: 21913096. DOI: 10.1007/978-1-61779-328-8\_7

Desai MK, Mastrangelo MA, Ryan DA, Sudol KL, Narrow WC, Bowers WJ. Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. *Am J Pathol.* 2010; 177:1422–35. PMID: 20696774. DOI: 10.2353/ajpath.2010.100087 [PubMed: 20696774]

Desai MK, Sudol KL, Janelins MC, Mastrangelo MA, Frazer ME, Bowers WJ. Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. *Glia.* 2009; 57:54–65. PMID: 18661556. DOI: 10.1002/glia.20734 [PubMed: 18661556]

Di Castro MA, Chuquet J, Liaudet N, Bhaukaurally K, Santello M, Bouvier D, Tiret P, Volterra A. Local Ca<sup>2+</sup> detection and modulation of synaptic release by astrocytes. *Nat Neurosci.* 2011; 14:1276–84. PMID: 21909085. DOI: 10.1038/nn.2929 [PubMed: 21909085]

Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Golland R, Wichterle H, Henderson CE, Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. *Science.* 2008; 321:1218–21. doi: 1158799 [pii] 10.1126/science.1158799. PMID: 18669821. [PubMed: 18669821]

Ding Q, Regan SN, Xia Y, Oostrom LA, Cowan CA, Musunuru K. Enhanced Efficiency of Human Pluripotent Stem Cell Genome Editing through Replacing TALENs with CRISPRs. *Cell Stem Cell.* 2013; 12:393–394. PMID: 23561441. DOI: 10.1016/j.stem.2013.03.006 [PubMed: 23561441]

Ding Q, Lee Y-K, Schaefer EAK, Peters DT, Veres A, Kim K, Kuperwasser N, Motola DL, Meissner TB, Hendriks WT, Trevisan M, Gupta RM, Moisan A, Banks E, Friesen M, Schinzel RT, Xia F, Tang A, Xia Y, Figueroa E, Wann A, Ahfeldt T, Daheron L, Zhang F, Rubin LL, Peng LF, Chung RT, Musunuru K, Cowan CA. A TALEN Genome-Editing System for Generating Human Stem

Cell-Based Disease Models. *Cell Stem Cell*. 2013; 12:238–251. PMID: 23246482. DOI: 10.1016/j.stem.2012.11.011 [PubMed: 23246482]

- Dobbin MM, Madabhushi R, Pan L, Chen Y, Kim D, Gao J, Ahonon B, Pao PC, Qiu Y, Zhao Y, Tsai LH. SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons. *Nat Neurosci*. 2013 doi: nn.3460 [pii] 10.1038/nn.3460. PMID: 23852118.
- Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, Herb B, Ladd-Acosta C, Rho J, Loewer S, Miller J, Schlaeger T, Daley GQ, Feinberg AP. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. *Nat Genet*. 2009; 41:1350–3. doi: ng.471 [pii] 10.1038/ng.471. PMID: 19881528. [PubMed: 19881528]
- Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS, Alzheimer's Disease Cooperative Study Steering C, Siemers E, Sethuraman G, Mohs R, Semagacestat Study G. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. *N Engl J Med*. 2013; 369:341–50. PMID: 23883379. DOI: 10.1056/NEJMoa1210951 [PubMed: 23883379]
- Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R. Alzheimer's Disease Cooperative Study Steering, C and Solanezumab Study, G. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. *N Engl J Med*. 2014; 370:311–21. PMID: 24450890. DOI: 10.1056/NEJMoa1312889 [PubMed: 24450890]
- Douvaras P, Wang J, Zimmer M, Hanchuk S, O'Bara MA, Sadiq S, Sim FJ, Goldman J, Fossati V. Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells. *Stem Cell Reports*. 2014; 3:250–9. PMID: 25254339. DOI: 10.1016/j.stemcr.2014.06.012 [PubMed: 25254339]
- Ebert AD, Yu J, Rose FF Jr, Mattis VB, Lorson CL, Thomson JA, Svendsen CN. Induced pluripotent stem cells from a spinal muscular atrophy patient. *Nature*. 2009; 457:277–80. doi: nature07677 [pii] 10.1038/nature07677. PMID: 19098894. [PubMed: 19098894]
- Eiraku M, Sasai Y. Self-formation of layered neural structures in three-dimensional culture of ES cells. *Curr Opin Neurobiol*. 2012; 22:768–77. PMID: 22405989. DOI: 10.1016/j.conb.2012.02.005 [PubMed: 22405989]
- Eiraku M, Watanabe K, Matsuo-Takasaki M, Kawada M, Yonemura S, Matsumura M, Wataya T, Nishiyama A, Muguruma K, Sasai Y. Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. *Cell Stem Cell*. 2008; 3:519–32. PMID: 18983967. DOI: 10.1016/j.stem.2008.09.002 [PubMed: 18983967]
- Englund E, Brun A, Alling C. White matter changes in dementia of Alzheimer's type. Biochemical and neuropathological correlates. *Brain*. 1988; 111(Pt 6):1425–39. PMID: 3208064. [PubMed: 3208064]
- Espuny-Camacho I, Michelsen KA, Gall D, Linaro D, Hasche A, Bonnefont J, Bali C, Orduz D, Bilheu A, Herpoel A, Lambert N, Gaspard N, Peron S, Schiffmann SN, Giugliano M, Gaillard A, Vanderhaeghen P. Pyramidal neurons derived from human pluripotent stem cells integrate efficiently into mouse brain circuits in vivo. *Neuron*. 2013; 77:440–56. PMID: 23395372. DOI: 10.1016/j.neuron.2012.12.011 [PubMed: 23395372]
- Etemad S, Zamin RM, Ruitenber MJ, Filgueira L. A novel in vitro human microglia model: characterization of human monocyte-derived microglia. *J Neurosci Methods*. 2012; 209:79–89. PMID: 22659341. DOI: 10.1016/j.jneumeth.2012.05.025 [PubMed: 22659341]
- Evans MJ, Kaufman MH. Establishment in Culture of Pluripotential Cells from Mouse Embryos. *Nature*. 1981; 292:154–156. PMID: 7242681. DOI: 10.1038/292154a0 [PubMed: 7242681]
- Falk A, Koch P, Kesavan J, Takashima Y, Ladewig J, Alexander M, Wiskow O, Tailor J, Trotter M, Pollard S, Smith A, Brustle O. Capture of neuroepithelial-like stem cells from pluripotent stem cells provides a versatile system for in vitro production of human neurons. *PLoS One*. 2012; 7:e29597. (22272239). [PubMed: 22272239]
- Farrer LA, Cupples La Fau - Haines JL, Haines JI Fau - Hyman B, Hyman B Fau - Kukull WA, Kukull Wa Fau - Mayeux R, Mayeux R Fau - Myers RH, Myers Rh Fau - Pericak-Vance MA, Pericak-Vance Ma Fau - Risch N, Risch N Fau - van Duijn CM, van Duijn CM. Effects of age, sex, and

- ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA*. 1997 PMID: 9343467.
- Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. *Neuron*. 2005; 48:825–838. [PubMed: 16337919]
- Fishell G, Heintz N. The Neuron Identity Problem: Form Meets Function. *Neuron*. 2013; 80:602–612. PMID: 24183013. DOI: 10.1016/j.neuron.2013.10.035 [PubMed: 24183013]
- Fong H, Wang C, Knoferle J, Walker D, Balestra ME, Tong LM, Leung L, Ring KL, Seeley WW, Karydas A, Kshirsagar MA, Boxer AL, Kosik KS, Miller BL, Huang Y. Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. *Stem Cell Reports*. 2013; 1:226–34. PMID: 24319659. DOI: 10.1016/j.stemcr.2013.08.001 [PubMed: 24319659]
- Foo LC, Allen NJ, Bushong EA, Ventura PB, Chung WS, Zhou L, Cahoy JD, Daneman R, Zong H, Ellisman MH, Barres BA. Development of a method for the purification and culture of rodent astrocytes. *Neuron*. 2011; 71:799–811. PMID: 21903074. DOI: 10.1016/j.neuron.2011.07.022 [PubMed: 21903074]
- Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM. Human apolipoprotein E4 alters the amyloid- $\beta$  40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. *Journal of Neuroscience*. 2005; 25:2803–2810. [PubMed: 15772340]
- Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL. Role of genes and environments for explaining Alzheimer disease. *Arch Gen Psychiatry*. 2006; 63:168–74. PMID: 16461860. DOI: 10.1001/archpsyc.63.2.168 [PubMed: 16461860]
- Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science*. 2010; 330:841–845. PMID: 20966214. [PubMed: 20966214]
- Gjoneska E, Pfenning AR, Mathys H, Quon G, Kundaje A, Tsai LH, Kellis M. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. *Nature*. 2015; 518:365–9. PMID: 25693568. DOI: 10.1038/nature14252 [PubMed: 25693568]
- Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. *Biochemical and Biophysical Research Communications*. 1984; 120:885–890. [PubMed: 6375662]
- Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. 1991; 349:704–706. [PubMed: 1671712]
- Goate A. Segregation of a missense mutation in the amyloid beta-protein precursor gene with familial Alzheimer's disease. *J Alzheimers Dis*. 2006; 9:341–7. PMID: 16914872. [PubMed: 16914872]
- Goldgaber D, Lerman MI, McBride WO, Saffiotti U, Gajdusek DC. Isolation, characterization, and chromosomal localization of human brain cDNA clones coding for the precursor of the amyloid of brain in Alzheimer's disease, Down's syndrome and aging. *J Neural Transm Suppl*. 1987; 24:23–8. PMID: 2960782. [PubMed: 2960782]
- Goto M. Hierarchical deterioration of body systems in Werner's syndrome: Implications for normal ageing. *Mechanisms of Ageing and Development*. 1997; 98:239–254. [PubMed: 9352493]
- Götz J, Deters N, Doldissen A, Bokhari L, Ke Y, Wiesner A, Schonrock N, Ittner LM. A Decade of Tau Transgenic Animal Models and Beyond. *Brain Pathology*. 2007; 17:91–103. DOI: 10.1111/j.1750-3639.2007.00051.x [PubMed: 17493043]
- Graeber MB, Kosel S, Egensperger R, Banati RB, Muller U, Bise K, Hoff P, Moller HJ, Fujisawa K, Mehraein P. Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis. *Neurogenetics*. 1997; 1:73–80. PMID: 10735278. [PubMed: 10735278]
- Grange P, Bohland JW, Okaty BW, Sugino K, Bokil H, Nelson SB, Ng L, Hawrylycz M, Mitra PP. Cell-type-based model explaining coexpression patterns of genes in the brain. *Proceedings of the*

- National Academy of Sciences of the United States of America. 2014; 111:5397–5402. PMID: 24706869. DOI: 10.1073/pnas.1312098111 [PubMed: 24706869]
- Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. *J Biol Chem.* 1986; 261:6084–9. PMID: 3084478. [PubMed: 3084478]
- Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J, Alzheimer Genetic Analysis G. TREM2 variants in Alzheimer's disease. *N Engl J Med.* 2013; 368:117–27. PMID: 23150934. DOI: 10.1056/NEJMoa1211851 [PubMed: 23150934]
- Hanna JH, Saha K, Jaenisch R. Pluripotency and Cellular Reprogramming: Facts, Hypotheses, Unresolved Issues. *Cell.* 2010; 143:508–525. PMID: 21074044. DOI: 10.1016/j.cell.2010.10.008 [PubMed: 21074044]
- Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskva V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel K-H, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet.* 2009; 41:1088–1093. doi: [http://www.nature.com/journal/v41/n10/suppinfo/ng.440\\_S1.html](http://www.nature.com/journal/v41/n10/suppinfo/ng.440_S1.html). [PubMed: 19734902]
- Hasty P, Campisi J, Hoeijmakers J, van Steeg H, Vijg J. Aging and Genome Maintenance: Lessons from the Mouse? *Science.* 2003; 299:1355–1359. DOI: 10.1126/science.1079161 [PubMed: 12610296]
- Haydon PG, Nedergaard M. How do astrocytes participate in neural plasticity? *Cold Spring Harb Perspect Biol.* 2015; 7:a020438. PMID: 25502516. doi: 10.1101/cshperspect.a020438
- Hazra A, Gu F, Aulakh A, Berridge C, Eriksen JL, Ziburkus J. Inhibitory neuron and hippocampal circuit dysfunction in an aged mouse model of Alzheimer's disease. *PLoS One.* 2013; 8:e64318. PMID: 23691195. doi: 10.1371/journal.pone.0064318 [PubMed: 23691195]
- Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. *Neurology.* 2013; PMID: 23390181. doi: 10.1212/WNL.0b013e31828726f5
- Hertz L, Peng L, Lai JC. Functional studies in cultured astrocytes. *Methods.* 1998; 16:293–310. PMID: 10071068. DOI: 10.1006/meth.1998.0686 [PubMed: 10071068]
- Hibaoui Y, Grad I, Letourneau A, Sailani MR, Dahoun S, Santoni FA, Gimelli S, Guipponi M, Pelte MF, Bena F, Antonarakis SE, Feki A. Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21. *EMBO Mol Med.* 2014; 6:259–77. PMID: 24375627. DOI: 10.1002/emmm.201302848 [PubMed: 24375627]
- Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M, DeKaveler RC, Katibah GE, Amora R, Boydston EA, Zeitler B, Meng X, Miller JC, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Jaenisch R. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. *Nat Biotechnol.* 2009; 27:851–7. PMID: 19680244. DOI: 10.1038/nbt.1562 [PubMed: 19680244]
- Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ, Zhang L, Santiago Y, Miller JC, Zeitler B, Cherone JM, Meng X, Hinkley SJ, Rebar EJ, Gregory PD, Urnov FD, Jaenisch R. Genetic engineering of human pluripotent cells using TALE nucleases. *Nature Biotechnology.* 2011; 29:731–734. PMID: 21738127. DOI: 10.1038/nbt.1927



- Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Ruther E, Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Gallacher J, Hull M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, Alzheimer's Disease Neuroimaging I; van Duijn CM, Breteler MM, Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S, consortium, C; Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alperovitch A, Lathrop M, consortium, E. Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Bjornsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossu P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet.* 2011; 43:429–35. PMID: 21460840. DOI: 10.1038/ng.803 [PubMed: 21460840]
- Hossini AM, Megges M, Prigione A, Lichtner B, Toliat MR, Wruck W, Schroter F, Nuernberg P, Kroll H, Makrantonaki E, Zoubouliss CC, Adjaye J. Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer's disease donor as a model for investigating AD-associated gene regulatory networks. *BMC Genomics.* 2015; 16:84. PMID: 25765079. doi: 10.1186/s12864-015-1262-5 [PubMed: 25765079]
- Hotta Y. Ethical issues of the research on human embryonic stem cells. *J Int Bioethique.* 2008; 19:77–85. 124–5. PMID: 19244943. [PubMed: 19244943]
- Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. *Cell.* 2014; 157:1262–78. PMID: 24906146. DOI: 10.1016/j.cell.2014.05.010 [PubMed: 24906146]
- Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, Cradick TJ, Marraffini LA, Bao G, Zhang F. DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat Biotechnol.* 2013; 31:827–32. PMID: 23873081. DOI: 10.1038/nbt.2647 [PubMed: 23873081]
- Hu B-Y, Weick JP, Yu J, Ma L-X, Zhang X-Q, Thomson JA, Zhang S-C. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. *Proceedings of the National Academy of Sciences.* 2010; 107:4335–4340. DOI: 10.1073/pnas.0910012107
- Hu BY, Du ZW, Zhang SC. Differentiation of human oligodendrocytes from pluripotent stem cells. *Nat Protoc.* 2009; 4:1614–22. PMID: 19834476. DOI: 10.1038/nprot.2009.186 [PubMed: 19834476]
- Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden HH, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevena M, De Graaff E, Wauters E, Van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JBJ, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Costra BA, Hardy J, Goate A, Van Swieten J, Mann D, Lynch T, Heutink P. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature.* 1998; 393:702–704. PMID: 9641683. [PubMed: 9641683]
- Iovino M, Agathou S, Gonzalez-Rueda A, Del Castillo Velasco-Herrera M, Borroni B, Alberici A, Lynch T, O'Dowd S, Geti I, Gaffney D, Vallier L, Paulsen O, Karadottir RT, Spillantini MG.



- Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations. *Brain*. 2015; PMID: 26220942. doi: 10.1093/brain/awv222
- Isoobe K, Cheng Z, Nishio N, Suganya T, Tanaka Y, Ito S. iPSCs, aging and age-related diseases. *N Biotechnol*. 2014; 31:411–21. PMID: 24784583. DOI: 10.1016/j.nbt.2014.04.004 [PubMed: 24784583]
- Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature*. 2012; 482:216–20. PMID: 22278060. DOI: 10.1038/nature10821 [PubMed: 22278060]
- Jang J, Kang HC, Kim HS, Kim JY, Huh YJ, Kim DS, Yoo JE, Lee JA, Lim B, Lee J, Yoon TM, Park IH, Hwang DY, Daley GQ, Kim DW. Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. *Ann Neurol*. 2011; 70:402–9. PMID: 21721033. DOI: 10.1002/ana.22486 [PubMed: 21721033]
- Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. *Biochemistry*. 1993; 32:4693–7. PMID: 8490014. [PubMed: 8490014]
- Jessen NA, Munk AS, Lundgaard I, Nedergaard M. The Glymphatic System: A Beginner's Guide. *Neurochem Res*. 2015; PMID: 25947369. doi: 10.1007/s11064-015-1581-6
- Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*. 2012; 337:816–821. [PubMed: 22745249]
- Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K. Variant of TREM2 associated with the risk of Alzheimer's disease. *N Engl J Med*. 2013; 368:107–16. PMID: 23150908. DOI: 10.1056/NEJMoa1211103 [PubMed: 23150908]
- Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. *Nat Rev Mol Cell Biol*. 2013; 14:49–55. PMID: 23169466. DOI: 10.1038/nrm3486 [PubMed: 23169466]
- Kadoshima T, Sakaguchi H, Nakano T, Soen M, Ando S, Eiraku M, Sasai Y. Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex. *Proc Natl Acad Sci U S A*. 2013; 110:20284–9. PMID: 24277810. DOI: 10.1073/pnas.1315710110 [PubMed: 24277810]
- Kamm FM. Ethical issues in using and not using embryonic stem cells. *Stem Cell Rev*. 2005; 1:325–30. PMID: 17142875. DOI: 10.1385/SCR:1:4:325 [PubMed: 17142875]
- Kanekiyo T, Xu H, Bu G. ApoE and Abeta in Alzheimer's disease: accidental encounters or partners? *Neuron*. 2014; 81:740–54. PMID: 24559670. DOI: 10.1016/j.neuron.2014.01.045 [PubMed: 24559670]
- Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature*. 1987; 325:733–6. PMID: 2881207. DOI: 10.1038/325733a0 [PubMed: 2881207]
- Khakh BS, McCarthy KD. Astrocyte calcium signaling: from observations to functions and the challenges therein. *Cold Spring Harb Perspect Biol*. 2015; 7:a020404. PMID: 25605709. doi: 10.1101/cshperspect.a020404 [PubMed: 25605709]
- Khurana V, Tardiff DF, Chung CY, Lindquist S. Toward stem cell-based phenotypic screens for neurodegenerative diseases. *Nat Rev Neurol*. 2015; 11:339–350. PMID: 25986505. DOI: 10.1038/nrneurol.2015.79 [PubMed: 25986505]
- Kim D, Frank CL, Dobbin MM, Tsunemoto RK, Tu W, Peng PL, Guan JS, Lee BH, Moy LY, Giusti P, Broodie N, Mazitschek R, Delalle I, Haggarty SJ, Neve RL, Lu Y, Tsai LH. Dereglulation of HDAC1 by p25/Cdk5 in Neurotoxicity. *Neuron*. 2008; 60:803–817. PMID: 19081376. [PubMed: 19081376]
- Kim DS, Lee DR, Kim HS, Yoo JE, Jung SJ, Lim BY, Jang J, Kang HC, You S, Hwang DY, Leem JW, Nam TS, Cho SR, Kim DW. Highly pure and expandable PSA-NCAM-positive neural precursors

- from human ESC and iPSC-derived neural rosettes. *PLoS One*. 2012; 7:e39715. PMID: 22911689. doi: 10.1371/journal.pone.0039715 [PubMed: 22911689]
- Kim H, Lee G, Ganat Y, Papapetrou EP, Lipchina I, Socci ND, Sadelain M, Studer L. miR-371-3 Expression Predicts Neural Differentiation Propensity in Human Pluripotent Stem Cells. *Cell Stem Cell*. 2011; 8:695–706. PMID: 21624813. DOI: 10.1016/j.stem.2011.04.002 [PubMed: 21624813]
- Kim J, Basak JM, Holtzman DM. The Role of Apolipoprotein E in Alzheimer's Disease. *Neuron*. 2009; 63:287–303. PMID: 19679070. [PubMed: 19679070]
- Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee MJ, Ji H, Ehrlich LIR, Yabuuchi A, Takeuchi A, Cunniff KC, Hongguang H, McKinney-Freeman S, Naveiras O, Yoon TJ, Irizarry RA, Jung N, Seita J, Hanna J, Murakami P, Jaenisch R, Weissleder R, Orkin SH, Weissman IL, Feinberg AP, Daley GQ. Epigenetic memory in induced pluripotent stem cells. *Nature*. 2010; 467:285–U60. PMID: 20644535. DOI: 10.1038/nature09342 [PubMed: 20644535]
- Kim YH, Choi SH, D'Avanzo C, Hebisch M, Sliwinski C, Bylykbashi E, Washicosky KJ, Klee JB, Brustle O, Tanzi RE, Kim DY. A 3D human neural cell culture system for modeling Alzheimer's disease. *Nat Protoc*. 2015; 10:985–1006. PMID: 26068894. DOI: 10.1038/nprot.2015.065 [PubMed: 26068894]
- King NM, Perrin J. Ethical issues in stem cell research and therapy. *Stem Cell Res Ther*. 2014; 5:85. PMID: 25157428. doi: 10.1186/scrt474 [PubMed: 25157428]
- Kobayashi K, Hayashi M, Nakano H, Fukutani Y, Sasaki K, Shimazaki M, Koshino Y. Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimer's disease. *Neuropathol Appl Neurobiol*. 2002; 28:238–51. PMID: 12060348. [PubMed: 12060348]
- Koch P, Tamboli IY, Mertens J, Wunderlich P, Ladewig J, Stuber K, Esselmann H, Wiltfang J, Brustle O, Walter J. Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of gamma-secretase activity in endogenous amyloid-beta generation. *Am J Pathol*. 2012; 180:2404–16. PMID: 22510327. DOI: 10.1016/j.ajpath.2012.02.012 [PubMed: 22510327]
- Koche RP, Smith ZD, Adli M, Gu HC, Ku MC, Gnirke A, Bernstein BE, Meissner A. Reprogramming Factor Expression Initiates Widespread Targeted Chromatin Remodeling. *Cell Stem Cell*. 2011; 8:96–105. PMID: 21211784. DOI: 10.1016/j.stem.2010.12.001 [PubMed: 21211784]
- Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K, Takahashi K, Asaka I, Aoi T, Watanabe A, Watanabe K, Kadoya C, Nakano R, Watanabe D, Maruyama K, Hori O, Hibino S, Choshi T, Nakahata T, Hioki H, Kaneko T, Naitoh M, Yoshikawa K, Yamawaki S, Suzuki S, Hata R, Ueno S, Seki T, Kobayashi K, Toda T, Murakami K, Irie K, Klein WL, Mori H, Asada T, Takahashi R, Iwata N, Yamanaka S, Inoue H. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. *Cell Stem Cell*. 2013; 12:487–96. PMID: 23434393. DOI: 10.1016/j.stem.2013.01.009 [PubMed: 23434393]
- Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. *Proc Natl Acad Sci U S A*. 1986; 83:4044–8. PMID: 2424016. [PubMed: 2424016]
- Kraepelin, E. *Psychiatrie*. Barth: Leipzig; 1910.
- Krantic S, Isorce N, Mechawar N, Davoli MA, Vignault E, Albuquerque M, Chabot JG, Moysé E, Chauvin JP, Aubert I, McLaurin J, Quirion R. Hippocampal GABAergic neurons are susceptible to amyloid-beta toxicity in vitro and are decreased in number in the Alzheimer's disease TgCRND8 mouse model. *J Alzheimers Dis*. 2012; 29:293–308. PMID: 22232004. DOI: 10.3233/JAD-2011-110830 [PubMed: 22232004]
- Krencik R, Weick JP, Liu Y, Zhang ZJ, Zhang SC. Specification of transplantable astroglial subtypes from human pluripotent stem cells. *Nat Biotechnol*. 2011; 29:528–34. PMID: 21602806. DOI: 10.1038/nbt.1877 [PubMed: 21602806]
- Krencik R, Zhang SC. Directed differentiation of functional astroglial subtypes from human pluripotent stem cells. *Nat Protoc*. 2011; 6:1710–7. PMID: 22011653. DOI: 10.1038/nprot.2011.405 [PubMed: 22011653]

- Lai S, Zhang M, Xu D, Zhang Y, Qiu L, Tian C, Zheng JC. Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment. *Transl Neurodegener.* 2015; 4:7. PMID: 25949812. doi: 10.1186/s40035-015-0028-y [PubMed: 25949812]
- Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, European Alzheimer's Disease Initiative, I. de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet.* 2009; 41:1094–9. PMID: 19734903. DOI: 10.1038/ng.439 [PubMed: 19734903]
- Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, Jun G, Destefano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Hollingworth P, Ramirez A, Hanon O, Fitzpatrick AL, Buxbaum JD, Campion D, Crane PK, Baldwin C, Becker T, Gudnason V, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Moron FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fievet N, Huentelman MJ, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossu P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, European Alzheimer's Disease, I, Genetic, Environmental Risk in Alzheimer's, D, Alzheimer's Disease Genetic, C, Cohorts for, H, Aging Research in Genomic, E, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannfelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH Jr, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltunen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nothen MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskva V, Seshadri S, Williams J, Schellenberg GD, Amouyel P. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet.* 2013; PMID: 24162737. doi: 10.1038/ng.2802
- Lambert JC, Grenier-Boley B, Chouraki V, Heath S, Zelenika D, Fievet N, Hannequin D, Pasquier F, Hanon O, Brice A, Epelbaum J, Berr C, Dartigues JF, Tzourio C, Campion D, Lathrop M, Amouyel P. Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. *J Alzheimers Dis.* 2010; 20:1107–18. PMID: 20413860. DOI: 10.3233/JAD-2010-100018 [PubMed: 20413860]
- Lancaster MA, Renner M, Martin C-A, Wenzel D, Bicknell LS, Hurles ME, Homfray T, Penninger JM, Jackson AP, Knoblich JA. Cerebral organoids model human brain development and microcephaly. *Nature.* 2013; 501:373. PMID: 23995685. doi: 10.1038/nature12517 [PubMed: 23995685]
- Lancaster MA, Knoblich JA. Generation of cerebral organoids from human pluripotent stem cells. *Nat Protoc.* 2014; 9:2329–40. PMID: 25188634. DOI: 10.1038/nprot.2014.158 [PubMed: 25188634]
- Lassmann H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, Wisniewski HM. Cell-Death in Alzheimers-Disease Evaluated by DNA Fragmentation in-Situ. *Acta Neuropathologica.* 1995; 89:35–41. PMID: 7709729. [PubMed: 7709729]
- Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, Ganat YM, Menon J, Shimizu F, Viale A, Tabar V, Sadelain M, Studer L. Modelling pathogenesis and treatment of

- familial dysautonomia using patient-specific iPSCs. *Nature*. 2009; 461:402–406. PMID: 19693009. [PubMed: 19693009]
- Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, Neve R, Ahljianian MK, Tsai LH. APP processing is regulated by cytoplasmic phosphorylation. *J Cell Biol*. 2003; 163:83–95. jcb.200301115 [pii]. PMID: 14557249. DOI: 10.1083/jcb.200301115 [PubMed: 14557249]
- Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. *Neurobiol Dis*. 1996; 3:16–32. PMID: 9173910. DOI: 10.1006/nbdi.1996.0003 [PubMed: 9173910]
- Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, Bird TD, Schellenberg GD. A familial Alzheimer's disease locus on chromosome 1. *Science*. 1995; 269:970–3. PMID: 7638621. [PubMed: 7638621]
- Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science*. 1995; 269:973–7. PMID: 7638622. [PubMed: 7638622]
- Li S, Mallory M, Alford M, Tanaka S, Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. *J Neuropathol Exp Neurol*. 1997; 56:901–11. PMID: 9258260. [PubMed: 9258260]
- Lippmann ES, Al-Ahmad A, Azarin SM, Palecek SP, Shusta EV. A retinoic acid-enhanced, multicellular human blood-brain barrier model derived from stem cell sources. *Sci Rep*. 2014; 4:4160. PMID: 24561821. doi: 10.1038/srep04160 [PubMed: 24561821]
- Lippmann ES, Al-Ahmad A, Palecek SP, Shusta EV. Modeling the blood-brain barrier using stem cell sources. *Fluids Barriers CNS*. 2013; 10:2. PMID: 23305164. doi: 10.1186/2045-8118-10-2 [PubMed: 23305164]
- Lippmann ES, Azarin SM, Kay JE, Nessler RA, Wilson HK, Al-Ahmad A, Palecek SP, Shusta EV. Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. *Nature Biotechnology*. 2012; 30:783–791. PMID: 22729031. DOI: 10.1038/nbt.2247
- Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O'Malley R, Castanon R, Klugman S, Downes M, Yu R, Stewart R, Ren B, Thomson JA, Evans RM, Ecker JR. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. *Nature*. 2011; 471:68–U84. PMID: 21289626. DOI: 10.1038/nature09798 [PubMed: 21289626]
- Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nature Reviews Neurology*. 2013 PMID: 23296339.
- Liu GH, Barkho BZ, Ruiz S, Diep D, Qu J, Yang SL, Panopoulos AD, Suzuki K, Kurian L, Walsh C, Thompson J, Boue S, Fung HL, Sancho-Martinez I, Zhang K, Yates J 3rd, Izpisua Belmonte JC. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. *Nature*. 2011; 472:221–5. PMID: 21346760. DOI: 10.1038/nature09879 [PubMed: 21346760]
- Liu GH, Qu J, Suzuki K, Nivet E, Li M, Montserrat N, Yi F, Xu X, Ruiz S, Zhang W, Wagner U, Kim A, Ren B, Li Y, Goebel A, Kim J, Soligalla RD, Dubova I, Thompson J, Yates J 3rd, Esteban CR, Sancho-Martinez I, Izpisua Belmonte JC. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. *Nature*. 2012; 491:603–7. PMID: 23075850. DOI: 10.1038/nature11557 [PubMed: 23075850]
- Liu H, Zhang SC. Specification of neuronal and glial subtypes from human pluripotent stem cells. *Cell Mol Life Sci*. 2011; 68:3995–4008. PMID: 21786144. DOI: 10.1007/s00018-011-0770-y [PubMed: 21786144]
- Liu Y, Liu H, Sauvey C, Yao L, Zarnowska ED, Zhang SC. Directed differentiation of forebrain GABA interneurons from human pluripotent stem cells. *Nat Protoc*. 2013; 8:1670–9. PMID: 23928500. DOI: 10.1038/nprot.2013.106 [PubMed: 23928500]
- Lomax GP, Hull SC, Isasi R. The DISCUSS Project: Revised Points to Consider for the Derivation of Induced Pluripotent Stem Cell Lines From Previously Collected Research Specimens. *Stem Cells Transl Med*. 2015; 4:123–9. PMID: 25561681. DOI: 10.5966/sctm.2014-0192 [PubMed: 25561681]
- Lomax GP, Peckman SR. Stem cell policy exceptionalism: proceed with caution. *Stem Cell Rev*. 2012; 8:299–304. PMID: 21837381. DOI: 10.1007/s12015-011-9305-z [PubMed: 21837381]

- Lomax GP, Hull SC, Lowenthal J, Rao M, Isasi R. The DISCUSS Project: induced pluripotent stem cell lines from previously collected research biospecimens and informed consent: points to consider. *Stem Cells Transl Med.* 2013; 2:727–30. PMID: 23990574. DOI: 10.5966/sctm.2013-0099 [PubMed: 23990574]
- Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. *Nucleic Acids Research.* 2007; 35:7497–7504. [PubMed: 17947327]
- Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA. Gene regulation and DNA damage in the ageing human brain. *Nature.* 2004; 429:883–891. [PubMed: 15190254]
- Lue LF, Walker DG, Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. *Neurobiology of Aging.* 2001; 22:945–956. PMID: 11755003. DOI: 10.1016/s0197-4580(01)00311-6 [PubMed: 11755003]
- Ma N, Shan Y, Liao B, Kong G, Wang C, Huang K, Zhang H, Cai X, Chen S, Pei D, Chen N, Pan G. Factor-induced Reprogramming and Zinc Finger Nuclease-aided Gene Targeting Cause Different Genome Instability in beta-Thalassemia Induced Pluripotent Stem Cells (iPSCs). *J Biol Chem.* 2015; 290:12079–89. PMID: 25795783. DOI: 10.1074/jbc.M114.624999 [PubMed: 25795783]
- Ma YJ, Hill DF, Creswick KE, Costa ME, Cornea A, Lioubin MN, Plowman GD, Ojeda SR. Neuregulins signaling via a glial erbB-2-erbB-4 receptor complex contribute to the neuroendocrine control of mammalian sexual development. *J Neurosci.* 1999; 19:9913–27. PMID: 10559400. [PubMed: 10559400]
- Maclean GA, Menne TF, Guo G, Sanchez DJ, Park IH, Daley GQ, Orkin SH. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. *Proc Natl Acad Sci U S A.* 2012; 109:17567–72. PMID: 23045682. DOI: 10.1073/pnas.1215468109 [PubMed: 23045682]
- Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science.* 1988;240. PMID: 3283935. [PubMed: 3140377]
- Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. *Annu Rev Genomics Hum Genet.* 2000 PMID: 11701639.
- Mahmoudi S, Brunet A. Aging and reprogramming: a two-way street. *Curr Opin Cell Biol.* 2012; 24:744–56. PMID: 23146768. DOI: 10.1016/j.ceb.2012.10.004 [PubMed: 23146768]
- Majewski J, Pastinen T. The study of eQTL variations by RNA-seq: from SNPs to phenotypes. *Trends in Genetics.* 2011; 27:72–79. PMID: 21122937. DOI: 10.1016/j.tig.2010.10.006 [PubMed: 21122937]
- Major T, Menon J, Auyeung G, Soldner F, Hockemeyer D, Jaenisch R, Tabar V. Transgene excision has no impact on in vivo integration of human iPSC derived neural precursors. *PLoS One.* 2011; 6:e24687. PMID: 21961042. doi: 10.1371/journal.pone.0024687 [PubMed: 21961042]
- Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-Guided Human Genome Engineering via Cas9. *Science (New York, NY).* 2013 doi: papers2://publication/doi/10.1126/science.1232033.
- Mann EO, Paulsen O. Role of GABAergic inhibition in hippocampal network oscillations. *Trends Neurosci.* 2007; 30:343–9. PMID: 17532059. DOI: 10.1016/j.tins.2007.05.003 [PubMed: 17532059]
- Marchetto MCN, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, Chen G, Gage FH, Muotri AR. A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells. *Cell.* 2010; 143:527–539. PMID: 21074045. DOI: 10.1016/j.cell.2010.10.016 [PubMed: 21074045]
- Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc Natl Acad Sci U S A.* 1981; 78:7634–8. PMID: 6950406. DOI: 10.1073/pnas.78.12.7634 [PubMed: 6950406]
- Masliah E, Alford M, Mallory M, Rockenstein E, Moechars D, Van Leuven F. Abnormal Glutamate Transport Function in Mutant Amyloid Precursor Protein Transgenic Mice. *Experimental Neurology.* 2000; 163:381–387. [PubMed: 10833311]
- Masumoto H, Ikuno T, Takeda M, Fukushima H, Marui A, Katayama S, Shimizu T, Ikeda T, Okano T, Sakata R, Yamashita JK. Human iPSC cell-engineered cardiac tissue sheets with cardiomyocytes



- and vascular cells for cardiac regeneration. *Sci Rep.* 2014; 4:6716. PMID: 25336194. doi: 10.1038/srep06716 [PubMed: 25336194]
- Mattis VB, Tom C, Akimov S, Saeedian J, Ostergaard ME, Southwell AL, Doty CN, Ornelas L, Sahabian A, Lenaeus L, Mandefro B, Sareen D, Arjomand J, Hayden MR, Ross CA, Svendsen CN. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. *Hum Mol Genet.* 2015; 24:3257–71. PMID: 25740845. DOI: 10.1093/hmg/ddv080 [PubMed: 25740845]
- McBride R. Pharma counts just 3 Alzheimer's drug wins in 13 years (101 losses!). *FierceBiotech.* 2012
- Mertens J, Stuber K, Wunderlich P, Ladewig J, Kesavan JC, Vandenberghe R, Vandembulcke M, van Damme P, Walter J, Brustle O, Koch P. APP processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based gamma-secretase modulation. *Stem Cell Reports.* 2013; 1:491–8. PMID: 24371804. DOI: 10.1016/j.stemcr.2013.10.011 [PubMed: 24371804]
- Miller J, Studer L. Aging in iPSC cells. *Aging (Albany NY).* 2014; 6:246–7. PMID: 24799443. [PubMed: 24799443]
- Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, Dulay GP, Hua KL, Ankoudinova I, Cost GJ, Urnov FD, Zhang HS, Holmes MC, Zhang L, Gregory PD, Rebar EJ. A TALE nuclease architecture for efficient genome editing. *Nat Biotechnol.* 2011; 29:143–8. PMID: 21179091. DOI: 10.1038/nbt.1755 [PubMed: 21179091]
- Miller JD, Ganat YM, Kishinevsky S, Bowman RL, Liu B, Tu EY, Mandal PK, Vera E, Shim JW, Kriks S, Taldone T, Fusaki N, Tomishima MJ, Krainc D, Milner TA, Rossi DJ, Studer L. Human iPSC-based modeling of late-onset disease via progerin-induced aging. *Cell Stem Cell.* 2013; 13:691–705. PMID: 24315443. DOI: 10.1016/j.stem.2013.11.006 [PubMed: 24315443]
- Minami H, Tashiro K, Okada A, Hirata N, Yamaguchi T, Takayama K, Mizuguchi H, Kawabata K. Generation of Brain Microvascular Endothelial-Like Cells from Human Induced Pluripotent Stem Cells by Co-Culture with C6 Glioma Cells. *PLoS One.* 2015; 10:e0128890. PMID: 26061227. doi: 10.1371/journal.pone.0128890 [PubMed: 26061227]
- Monoranu CM, Apfelbacher M, Gruenblatt E, Puppe B, Alafuzoff I, Ferrer I, Al-Saraj S, Keyvani K, Schmitt A, Falkai P, Schittenhelm J, Halliday G, Kril J, Harper C, McLean C, Riederer P, Roggendorf W. Abstracts of the 110th Meeting of the British Neuropathological Society. January 7–9, 2009. London, United Kingdom. *Neuropathol Appl Neurobiol.* 2009; 35(Suppl 1):1–38. PMID: 19146648. DOI: 10.1111/j.1365-2990.2008.01003.x [PubMed: 19146648]
- Muratore CR, Rice HC, Srikanth P, Callahan DG, Shin T, Benjamin LN, Walsh DM, Selkoe DJ, Young-Pearse TL. The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. *Hum Mol Genet.* 2014; 23:3523–36. PMID: 24524897. DOI: 10.1093/hmg/ddu064 [PubMed: 24524897]
- Murray A, Letourneau A, Canzonetta C, Stathaki E, Gimelli S, Sloan-Bena F, Abreheart R, Goh P, Lim S, Baldo C, Dagna-Bricarelli F, Hannan S, Mortensen M, Ballard D, Syndercombe Court D, Fusaki N, Hasegawa M, Smart TG, Bishop C, Antonarakis SE, Groet J, Nizetic D. Brief report: isogenic induced pluripotent stem cell lines from an adult with mosaic down syndrome model accelerated neuronal ageing and neurodegeneration. *Stem Cells.* 2015; 33:2077–84. PMID: 25694335. DOI: 10.1002/stem.1968 [PubMed: 25694335]
- Narsinh KH, Sun N, Sanchez-Freire V, Lee AS, Almeida P, Hu S, Jan T, Wilson KD, Leong D, Rosenberg J, Yao M, Robbins RC, Wu JC. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. *J Clin Invest.* 2011; 121:1217–21. PMID: 21317531. DOI: 10.1172/JCI44635 [PubMed: 21317531]
- Narsinh KH, Plews J, Wu JC. Comparison of human induced pluripotent and embryonic stem cells: fraternal or identical twins? *Mol Ther.* 2011; 19:635–8. PMID: 21455209. DOI: 10.1038/mt.2011.41 [PubMed: 21455209]
- Nazor KL, Altun G, Lynch C, Tran H, Harness JV, Slavin I, Garitaonandia I, Muller FJ, Wang YC, Boscolo FS, Fakunle E, Dumevska B, Lee S, Park HS, Olee T, D'Lima DD, Semechkin R, Parast MM, Galat V, Laslett AL, Schmidt U, Keirstead HS, Loring JF, Laurent LC. Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. *Cell Stem Cell.* 2012; 10:620–34. PMID: 22560082. DOI: 10.1016/j.stem.2012.02.013 [PubMed: 22560082]

- Neumann, HJ-B-S, 53123 Bonn, DE), Roy, Kristin (Karl-Barth-Str. 69, 53129 Bonn, DE), Brüstle, Oliver (c/o Institut für Rekonstruktive Neurobiologie Universität Bonn Sigmund-Freud-Str. 25, 53127 Bonn, DE), Peitz, Michael (Aloys-Schulte-Str. 28, 53129 Bonn, DE), (2012) Method for obtaining human microglial precursor cells from pluripotent stem cells. *Life & Brain GmbH* (Sigmund-Freud-Straße 25, 53127 Bonn, DE), Rheinische, Friedrich-wilhelms-universität (Regina-Pacis-Weg 3, 53113 Bonn, DE),,
- Nieweg K, Andreyeva A, van Stegen B, Tanriover G, Gottmann K. Alzheimer's disease-related amyloid-beta induces synaptotoxicity in human iPS cell-derived neurons. *Cell Death Dis.* 2015; 6:e1709. PMID: 25837485. doi: 10.1038/cddis.2015.72 [PubMed: 25837485]
- Oberheim NA, Wang X, Goldman S, Nedergaard M. Astrocytic complexity distinguishes the human brain. *Trends Neurosci.* 2006; 29:547–53. PMID: 16938356. DOI: 10.1016/j.tins.2006.08.004 [PubMed: 16938356]
- Oberheim NA, Takano T, Han X, He W, Lin JHC, Wang F, Xu Q, Wyatt JD, Pilcher W, Ojemann JG, Ransom BR, Goldman SA, Nedergaard M. Uniquely Hominid Features of Adult Human Astrocytes. *J. Neurosci.* 2009; 29:3276–3287. DOI: 10.1523/jneurosci.4707-08.2009 [PubMed: 19279265]
- Odawara A, Saitoh Y, Alhebshi AH, Gotoh M, Suzuki I. Long-term electrophysiological activity and pharmacological response of a human induced pluripotent stem cell-derived neuron and astrocyte co-culture. *Biochem Biophys Res Commun.* 2014; 443:1176–81. PMID: 24406164. DOI: 10.1016/j.bbrc.2013.12.142 [PubMed: 24406164]
- Ogawa S, Tokumoto Y, Miyake J, Nagamune T. Induction of oligodendrocyte differentiation from adult human fibroblast-derived induced pluripotent stem cells. *In Vitro Cell Dev Biol Anim.* 2011; 47:464–9. PMID: 21695581. DOI: 10.1007/s11626-011-9435-2 [PubMed: 21695581]
- Ohi Y, Qin H, Hong C, Blouin L, Polo JM, Guo T, Qi Z, Downey SL, Manos PD, Rossi DJ, Yu J, Hebrok M, Hochedlinger K, Costello JF, Song JS, Ramalho-Santos M. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. *Nat Cell Biol.* 2011; 13:541–9. PMID: 21499256. DOI: 10.1038/ncb2239 [PubMed: 21499256]
- Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A, Goshima N, Yamanaka S. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. *Stem Cells.* 2013; 31:458–66. PMID: 23193063. DOI: 10.1002/stem.1293 [PubMed: 23193063]
- Olgati P, Politis AM, Papadimitriou GN, De Ronchi D, Serretti A. Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways. *Int J Alzheimers Dis.* 2011; 2011:832379. PMID: 22191060. doi: 10.4061/2011/832379 [PubMed: 22191060]
- Parent JM, Anderson SA. Reprogramming patient-derived cells to study the epilepsies. *Nat Neurosci.* 2015; 18:360–6. PMID: 25710838. DOI: 10.1038/nn.3944 [PubMed: 25710838]
- Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ. Disease-specific induced pluripotent stem cells. *Cell.* 2008; 134:877–86. doi: S0092-8674(08)01001-5 [pii] 10.1016/j.cell.2008.07.041. PMID: 18691744. [PubMed: 18691744]
- Pasca AM, Sloan SA, Clarke LE, Tian Y, Makinson CD, Huber N, Kim CH, Park JY, O'Rourke NA, Nguyen KD, Smith SJ, Huguenard JR, Geschwind DH, Barres BA, Pasca SP. Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. *Nat Methods.* 2015; 12:671–8. PMID: 26005811. DOI: 10.1038/nmeth.3415 [PubMed: 26005811]
- Pascual O, Casper KB, Kubera C, Zhang J, Revilla-Sanchez R, Sul JY, Takano H, Moss SJ, McCarthy K, Haydon PG. Astrocytic purinergic signaling coordinates synaptic networks. *Science.* 2005; 310:113–6. doi: 310/5745/113 [pii] 10.1126/science.1116916. PMID: 16210541. [PubMed: 16210541]
- Perea G, Navarrete M, Araque A. Tripartite synapses: astrocytes process and control synaptic information. *Trends in Neurosciences.* 2009; 32:421–431. [PubMed: 19615761]
- Pfrieger FW. Roles of glial cells in synapse development. *Cell Mol Life Sci.* 2009; 66:2037–47. PMID: 19308323. DOI: 10.1007/s00018-009-0005-7 [PubMed: 19308323]
- Pfrieger FW, Barres BA. Synaptic efficacy enhanced by glial cells in vitro. *Science.* 1997; 277:1684–7. PMID: 9287225. [PubMed: 9287225]

- Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. *Mol Neurodegener.* 2010; 5:2. PMID: 20145736. doi: 10.1186/1750-1326-5-2 [PubMed: 20145736]
- Pouya A, Satarian L, Kiani S, Javan M, Baharvand H. Human induced pluripotent stem cells differentiation into oligodendrocyte progenitors and transplantation in a rat model of optic chiasm demyelination. *PLoS One.* 2011; 6:e27925. PMID: 22125639. doi: 10.1371/journal.pone.0027925 [PubMed: 22125639]
- Puschmann TB, Zanden C, De Pablo Y, Kirchhoff F, Pekna M, Liu J, Pekny M. Bioactive 3D cell culture system minimizes cellular stress and maintains the in vivo-like morphological complexity of astroglial cells. *Glia.* 2013; 61:432–40. PMID: 23292921. DOI: 10.1002/glia.22446 [PubMed: 23292921]
- Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell.* 2013; 152:1173–1183. [PubMed: 23452860]
- Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. *Nat Protoc.* 2013; 8:2281–308. PMID: 24157548. DOI: 10.1038/nprot.2013.143 [PubMed: 24157548]
- Robakis NK, Wisniewski HM, Jenkins EC, Devine-Gage EA, Houck GE, Yao XL, Ramakrishna N, Wolfe G, Silverman WP, Brown WT. Chromosome 21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. *Lancet.* 1987; 1:384–5. PMID: 2880184. [PubMed: 2880184]
- Robinson SR. Changes in the cellular distribution of glutamine synthetase in Alzheimer's disease. *J Neurosci Res.* 2001; 66:972–80. PMID: 11746426. [PubMed: 11746426]
- Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Llang Y, Chi H, Lin C, Holman K, Tsuda T, Mar L, Sorbi S, Nacmias B, Piacentini S, Amaducci L, Chumakov I, Cohen D, Lannfelt L, St George-Hyslop PH. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. *Nature.* 1995; 376:775–778. [PubMed: 7651536]
- Roth AD, Ramirez G, Alarcon R, Von Bernhardi R. Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. *Biol Res.* 2005; 38:381–7. PMID: 16579521. [PubMed: 16579521]
- Rouhani F, Kumasaka N, de Brito MC, Bradley A, Vallier L, Gaffney D. Genetic background drives transcriptional variation in human induced pluripotent stem cells. *PLoS Genet.* 2014; 10:e1004432. PMID: 24901476. doi: 10.1371/journal.pgen.1004432 [PubMed: 24901476]
- Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, Hockey A, Montgomery P, Beyreuther K, Masters CL. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. *The New England journal of medicine.* 1989; 320:1446–52. doi: papers://3039E21D-04C9-4FF4-AF76-9D1A38439DE0/Paper/p1254. [PubMed: 2566117]
- Ryan SD, Dolatabadi N, Chan SF, Zhang X, Akhtar MW, Parker J, Soldner F, Sunico CR, Nagar S, Talantova M, Lee B, Lopez K, Nutter A, Shan B, Molokanova E, Zhang Y, Han X, Nakamura T, Masliah E, Yates JR 3rd, Nakanishi N, Andreyev AY, Okamoto S, Jaenisch R, Ambasudhan R, Lipton SA. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription. *Cell.* 2013; 155:1351–64. PMID: 24290359. DOI: 10.1016/j.cell.2013.11.009 [PubMed: 24290359]
- Sahin E, DePinho RA. Linking functional decline of telomeres, mitochondria and stem cells during ageing. *Nature.* 2010; 464:520–528. [PubMed: 20336134]
- Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, Bapineuzumab, Clinical Trial I. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. *N Engl J Med.* 2014; 370:322–33. PMID: 24450891. DOI: 10.1056/NEJMoa1304839 [PubMed: 24450891]

- Samuel R, Daheron L, Liao S, Vardam T, Kamoun WS, Batista A, Buecker C, Schafer R, Han X, Au P, Scadden DT, Duda DG, Fukumura D, Jain RK. Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. *Proc Natl Acad Sci U S A*. 2013; 110:12774–9. PMID: 23861493. DOI: 10.1073/pnas.1310675110 [PubMed: 23861493]
- Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. *Nat Biotechnol*. 2014; 32:347–55. PMID: 24584096. DOI: 10.1038/nbt.2842 [PubMed: 24584096]
- Sandoe J, Eggan K. Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. *Nat Neurosci*. 2013; 16:780–9. PMID: 23799470. DOI: 10.1038/nn.3425 [PubMed: 23799470]
- Schellenberg GD, Payami H, Wijmsman EM, Orr HT, Goddard KA, Anderson L, Nemens E, White JA, Alonso ME, Ball MJ, et al. Chromosome 14 and late-onset familial Alzheimer disease (FAD). *Am J Hum Genet*. 1993; 53:619–28. PMID: 8352272. [PubMed: 8352272]
- Schwartz MP, Hou Z, Propson NE, Zhang J, Engstrom CJ, Costa VS, Jiang P, Nguyen BK, Bolin JM, Daly W, Wang Y, Stewart R, Page CD, Murphy WL, Thomson JA. Human pluripotent stem cell-derived neural constructs for predicting neural toxicity. *Proc Natl Acad Sci U S A*. 2015; 112:12516–21. PMID: 26392547. DOI: 10.1073/pnas.1516645112 [PubMed: 26392547]
- Selvaraj V, Jiang P, Chechneva O, Lo UG, Deng W. Differentiating human stem cells into neurons and glial cells for neural repair. *Front Biosci (Landmark Ed)*. 2012; 17:65–89. PMID: 22201733. [PubMed: 22201733]
- Sergent-Tanguy S, Chagneau C, Neveu I, Naveilhan P. Fluorescent activated cell sorting (FACS): a rapid and reliable method to estimate the number of neurons in a mixed population. *J Neurosci Methods*. 2003; 129:73–9. PMID: 12951234. DOI: 10.1016/s0165-0270(03)00210-3 [PubMed: 12951234]
- Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F. Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science*. 2014; 343:84–7. PMID: 24336571. DOI: 10.1126/science.1247005 [PubMed: 24336571]
- Shi Y, Kirwan P, Livesey FJ. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. *Nat Protoc*. 2012; 7:1836–46. PMID: 22976355. DOI: 10.1038/nprot.2012.116 [PubMed: 22976355]
- Shi Y, Kirwan P, Smith J, Robinson HP, Livesey FJ. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. *Nat Neurosci*. 2012; 15:477–86. s1. PMID: 22306606. DOI: 10.1038/nn.3041 [PubMed: 22306606]
- Shi Y, Kirwan P, Smith J, MacLean G, Orkin SH, Livesey FJ. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. *Sci Transl Med*. 2012; 4:124ra29. PMID: 22344463. doi: 10.1126/scitranslmed.3003771
- Shigetomi E, Bushong EA, Hausteiner MD, Tong X, Jackson-Weaver O, Kracun S, Xu J, Sofroniew MV, Ellisman MH, Khakh BS. Imaging calcium microdomains within entire astrocyte territories and endfeet with GCaMPs expressed using adeno-associated viruses. *J Gen Physiol*. 2013; 141:633–47. PMID: 23589582. DOI: 10.1085/jgp.201210949 [PubMed: 23589582]
- Shimamoto A, Yokote K, Tahara H. Werner Syndrome-specific induced pluripotent stem cells: recovery of telomere function by reprogramming. *Front Genet*. 2015; 6:10. PMID: 25688260. doi: 10.3389/fgene.2015.00010 [PubMed: 25688260]
- Siebert S, Cabuy E, Scherf BG, Kohler H, Panda S, Le YZ, Fehling HJ, Gaidatzis D, Stadler MB, Roska B. Transcriptional code and disease map for adult retinal cell types. *Nat Neurosci*. 2012; 15:487–95. S1–2. PMID: 22267162. DOI: 10.1038/nn.3032 [PubMed: 22267162]
- Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. *Science*. 2015
- Smith I, Silveirinha V, Stein JL, de la Torre-Ubieta L, Farrimond JA, Williamson EM, Whalley BJ. Human neural stem cell-derived cultures in three-dimensional substrates form spontaneously functional neuronal networks. *J Tissue Eng Regen Med*. 2015; PMID: 25712225. doi: 10.1002/term.2001
- Soldner F, Jaenisch R. iPSC disease modeling. *Science*. 2012; 338:1155–1156. [PubMed: 23197518]
- Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R. Parkinson's disease patient-derived induced pluripotent

stem cells free of viral reprogramming factors. *Cell*. 2009; 136:964–77. doi: S0092-8674(09)00151-2 [pii] 10.1016/j.cell.2009.02.013. PMID: 19269371. [PubMed: 19269371]

- Soldner F, Laganière J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, Khurana V, Golbe LI, Myers RH, Lindquist S, Zhang L, Guschin D, Fong LK, Vu BJ, Meng X, Urnov FD, Rebar EJ, Gregory PD, Zhang HS, Jaenisch R. Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations. *Cell*. 2011; 146:318–331. doi: papers2://publication/doi/10.1016/j.cell.2011.06.019. [PubMed: 21757228]
- Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. *Proc Natl Acad Sci U S A*. 1998; 95:7737–41. PMID: 9636220. [PubMed: 9636220]
- Spittaels K, Van Den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, Laenen I, Geerts H, Mercken M, Sciot R, Van Lommel A, Loos R, Van Leuven F. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. *American Journal Of Pathology*. 1999; 155:2153–2165. [PubMed: 10595944]
- Sproul AA, Jacob S, Pre D, Kim SH, Nestor MW, Navarro-Sobrinho M, Santa-Maria I, Zimmer M, Aubry S, Steele JW, Kahler DJ, Dranovsky A, Arancio O, Crary JF, Gandy S, Noggle SA. Characterization and molecular profiling of PSEN1 familial Alzheimer's disease iPSC-derived neural progenitors. *PLoS One*. 2014; 9:e84547. <http://dx.doi.org/10.1371/journal.pone.0084547>. [PubMed: 24416243]
- St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, Myers RH, Feldman RG, Pollen D, Drachman D, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. *Science*. 1987; 235:885–90. PMID: 2880399. [PubMed: 2880399]
- Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. *Acta Neuropathol*. 2009; 118:475–85. PMID: 19513731. DOI: 10.1007/s00401-009-0556-6 [PubMed: 19513731]
- Streit WJ, Xue QS. The Brain's Aging Immune System. *Aging Dis*. 2010; 1:254–261. PMID: 21833348. [PubMed: 21833348]
- Sugaya K, Reeves M, McKinney M. Topographic associations between DNA fragmentation and Alzheimer's disease neuropathology in the hippocampus. *Neurochemistry International*. 1997; 31:275–281. PMID: 9220460. DOI: 10.1016/S0197-0186(96)00158-1 [PubMed: 9220460]
- Sun W, McConnell E, Pare JF, Xu Q, Chen M, Peng W, Lovatt D, Han X, Smith Y, Nedergaard M. Glutamate-dependent neuroglial calcium signaling differs between young and adult brain. *Science*. 2013; 339:197–200. PMID: 23307741. DOI: 10.1126/science.1226740 [PubMed: 23307741]
- Swistowski A, Peng J, Liu Q, Mali P, Rao MS, Cheng L, Zeng X. Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. *Stem Cells*. 2010; 28:1893–904. PMID: 20715183. DOI: 10.1002/stem.499 [PubMed: 20715183]
- Tabata H. Diverse subtypes of astrocytes and their development during corticogenesis. *Front Neurosci*. 2015; 9:114. PMID: 25904839. doi: 10.3389/fnins.2015.00114 [PubMed: 25904839]
- Tada M, Takahama Y, Abe K, Nakatsuji N, Tada T. Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. *Curr Biol*. 2001; 11:1553–8. PMID: 11591326. DOI: 10.1016/s0960-9822(01)00459-6 [PubMed: 11591326]
- Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. 2007; 131:861–72. doi: S0092-8674(07)01471-7 [pii] 10.1016/j.cell.2007.11.019. PMID: 18035408. [PubMed: 18035408]
- Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. *Cell*. 2006; 126:663–676. [PubMed: 16904174]
- Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang RR, Ueno Y, Zheng YW, Koike N, Aoyama S, Adachi Y, Taniguchi H. Vascularized and functional human liver from an iPSC-derived organ bud transplant. *Nature*. 2013; 499:481–4. PMID: 23823721. DOI: 10.1038/nature12271 [PubMed: 23823721]



- Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. *Science*. 1987; 235:880–4. PMID: 2949367. [PubMed: 2949367]
- Telias M, Ben-Yosef D. Modeling neurodevelopmental disorders using human pluripotent stem cells. *Stem Cell Rev*. 2014; 10:494–511. PMID: 24728983. DOI: 10.1007/s12015-014-9507-2 [PubMed: 24728983]
- Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. *Science*. 1998; 282:1145–7. PMID: 9804556. [PubMed: 9804556]
- Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. *J Neurosci Res*. 2007; 85:2059–70. PMID: 17497670. DOI: 10.1002/jnr.21325 [PubMed: 17497670]
- Tonnesen J, Katona G, Rozsa B, Nagerl UV. Spine neck plasticity regulates compartmentalization of synapses. *Nat Neurosci*. 2014; 17:678–85. PMID: 24657968. DOI: 10.1038/nn.3682 [PubMed: 24657968]
- Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V, Wyvekens N, Khayter C, Iafrate AJ, Le LP, Aryee MJ, Joung JK. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. *Nat Biotechnol*. 2015; 33:187–97. PMID: 25513782. DOI: 10.1038/nbt.3117 [PubMed: 25513782]
- Tsuchiya T, Park KC, Toyonaga S, Yamada SM, Nakabayashi H, Nakai E, Ikawa N, Furuya M, Tominaga A, Shimizu K. Characterization of microglia induced from mouse embryonic stem cells and their migration into the brain parenchyma. *J Neuroimmunol*. 2005; 160:210–8. PMID: 15710475. DOI: 10.1016/j.jneuroim.2004.10.025 [PubMed: 15710475]
- Ullian EM, Harris BT, Wu A, Chan JR, Barres BA. Schwann cells and astrocytes induce synapse formation by spinal motor neurons in culture. *Mol Cell Neurosci*. 2004; 25:241–51. PMID: 15019941. DOI: 10.1016/j.mcn.2003.10.011 [PubMed: 15019941]
- Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. *Nat Rev Genet*. 2010; 11:636–46. PMID: 20717154. DOI: 10.1038/nrg2842 [PubMed: 20717154]
- Verwer RW, Dubelaar EJ, Hermens WT, Swaab DF. Tissue cultures from adult human postmortem subcortical brain areas. *J Cell Mol Med*. 2002; 6:429–32. PMID: 12417060. DOI: 10.1111/j.1582-4934.2002.tb00522.x [PubMed: 12417060]
- Wang L, Meece K, Williams DJ, Lo KA, Zimmer M, Heinrich G, Martin Carli J, Leduc CA, Sun L, Zeltser LM, Freeby M, Goland R, Tsang SH, Wardlaw SL, Egli D, Leibel RL. Differentiation of hypothalamic-like neurons from human pluripotent stem cells. *J Clin Invest*. 2015; 125:796–808. PMID: 25555215. DOI: 10.1172/JCI79220 [PubMed: 25555215]
- Wang S, Bates J, Li X, Schanz S, Chandler-Militello D, Levine C, Maherali N, Studer L, Hochedlinger K, Windrem M, Goldman SA. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. *Cell Stem Cell*. 2013; 12:252–64. PMID: 23395447. DOI: 10.1016/j.stem.2012.12.002 [PubMed: 23395447]
- Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. *Science*. 2014; 343:80–4. PMID: 24336569. DOI: 10.1126/science.1246981 [PubMed: 24336569]
- Wang WY, Pan L, Su SC, Quinn EJ, Sasaki M, Jimenez JC, Mackenzie IR, Huang EJ, Tsai LH. Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons. *Nat Neurosci*. 2013; 16:1383–91. PMID: 24036913. DOI: 10.1038/nn.3514 [PubMed: 24036913]
- Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van Eldik LJ. Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. *Frontiers in genetics*. 2014; 5:88–88. PMID: MEDLINE:24795750. DOI: 10.3389/fgene.2014.00088 [PubMed: 24795750]
- Weick JP, Held DL, Bonadurer GF 3rd, Doers ME, Liu Y, Maguire C, Clark A, Knackert JA, Molinarolo K, Musser M, Yao L, Yin Y, Lu J, Zhang X, Zhang SC, Bhattacharyya A. Deficits in human trisomy 21 iPSCs and neurons. *Proc Natl Acad Sci U S A*. 2013; 110:9962–7. PMID: 23716668. DOI: 10.1073/pnas.1216575110 [PubMed: 23716668]

- Wen J-Y, Wei C-Y, Shah K, Wong J, Wang C, Chen H-SV. Maturation-Based Model of Arrhythmogenic Right Ventricular Dysplasia Using Patient-Specific Induced Pluripotent Stem Cells. *Circulation Journal advpub*. 2015; doi: 10.1253/circj.CJ-15-0363
- Wen Z, Nguyen HN, Guo Z, Lalli MA, Wang X, Su Y, Kim N-S, Yoon K-J, Shin J, Zhang C, Makri G, Nauen D, Yu H, Guzman E, Chiang C-H, Yoritomo N, Kaibuchi K, Zou J, Christian KM, Cheng L, Ross CA, Margolis RL, Chen G, Kosik KS, Song H, Ming G-l. Synaptic dysregulation in a human iPSC cell model of mental disorders. *Nature*. 2014; 515:414–8. PMID: MEDLINE: 25132547. DOI: 10.1038/nature13716 [PubMed: 25132547]
- Wilmot I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. *Nature*. 1997; 385:810–3. PMID: 9039911. DOI: 10.1038/385810a0 [PubMed: 9039911]
- Wolozin B. Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design. *Alzheimers Res Ther*. 2012; 4:3. PMID: 22264400. doi: 10.1186/alzrt101 [PubMed: 22264400]
- Woodruff G, Young JE, Martinez FJ, Buen F, Gore A, Kinaga J, Li Z, Yuan SH, Zhang K, Goldstein LS. The presenilin-1 DeltaE9 mutation results in reduced gamma-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. *Cell Rep*. 2013; 5:974–85. PMID: 24239350. DOI: 10.1016/j.celrep.2013.10.018 [PubMed: 24239350]
- Woods YL, Cohen P, Becker W, Jakes R, Goedert M, Wang X, Proud CG. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. *Biochem J*. 2001; 355:609–15. PMID: 11311121. [PubMed: 11311121]
- Wren MC, Zhao J, Liu CC, Murray ME, Atagi Y, Davis MD, Fu Y, Okano HJ, Ogaki K, Strongosky AJ, Tacik P, Rademakers R, Ross OA, Dickson DW, Wszolek ZK, Kanekiyo T, Bu G. Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. *Mol Neurodegener*. 2015; 10:46. PMID: 26373282. doi: 10.1186/s13024-015-0042-7 [PubMed: 26373282]
- Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J. Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) by ectodomain shedding and gamma-secretase dependent intramembranous cleavage. *J Biol Chem*. 2013; PMID: 24078628. doi: 10.1074/jbc.M113.517540
- Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O'Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard M. Sleep drives metabolite clearance from the adult brain. *Science*. 2013; 342:373–7. PMID: 24136970. DOI: 10.1126/science.1241224 [PubMed: 24136970]
- Xu X, Lei Y, Luo J, Wang J, Zhang S, Yang XJ, Sun M, Nuwaysir E, Fan G, Zhao J, Lei L, Zhong Z. Prevention of beta-amyloid induced toxicity in human iPSC cell-derived neurons by inhibition of Cyclin-dependent kinases and associated cell cycle events. *Stem Cell Res*. 2013; 10:213–27. PMID: 23305945. DOI: 10.1016/j.scr.2012.11.005 [PubMed: 23305945]
- Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, Suzuki N. Modeling familial Alzheimer's disease with induced pluripotent stem cells. *Hum Mol Genet*. 2011; 20:4530–9. PMID: 21900357. DOI: 10.1093/hmg/ddr394 [PubMed: 21900357]
- Yahata N, Asai M, Kitaoka S, Takahashi K, Asaka I, Hioki H, Kaneko T, Maruyama K, Saido TC, Nakahata T, Asada T, Yamanaka S, Iwata N, Inoue H. Anti-Abeta drug screening platform using human iPSC cell-derived neurons for the treatment of Alzheimer's disease. *PLoS One*. 2011; 6:e25788. PMID: 21984949. doi: 10.1371/journal.pone.0025788 [PubMed: 21984949]
- Yang F, Sun X, Beech W, Teter B, Wu S, Sigel J, Vinters HV, Frautschy SA, Cole GM. Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease. *Am J Pathol*. 1998; 152:379–89. PMID: 9466564. [PubMed: 9466564]
- Yoshida M, Kitaoka S, Egawa N, Yamane M, Ikeda R, Tsukita K, Amano N, Watanabe A, Morimoto M, Takahashi J, Hosoi H, Nakahata T, Inoue H, Saito MK. Modeling the early phenotype at the neuromuscular junction of spinal muscular atrophy using patient-derived iPSCs. *Stem Cell Reports*. 2015; 4:561–8. PMID: 25801509. DOI: 10.1016/j.stemcr.2015.02.010 [PubMed: 25801509]

- Yoshimizu T, Pan JQ, Mungenast AE, Madison JM, Su S, Ketterman J, Ongur D, McPhie D, Cohen B, Perlis R, Tsai LH. Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons. *Mol Psychiatry*. 2015; 20:284. PMID: 25623946. doi: 10.1038/mp.2014.181 [PubMed: 25623946]
- Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, Kim J, Eimer WA, Estus S, Rebeck GW, Weeber EJ, Bu G, Yu C, LaDu MJ. APOE4-specific changes in A $\beta$  accumulation in a new transgenic mouse model of alzheimer disease. *Journal of Biological Chemistry*. 2012; 287:41774–41786. [PubMed: 23060451]
- Young JE, Boulanger-Weill J, Williams DA, Woodruff G, Buen F, Revilla AC, Herrera C, Israel MA, Yuan SH, Edland SD, Goldstein LS. Elucidating molecular phenotypes caused by the SORL1 Alzheimer's disease genetic risk factor using human induced pluripotent stem cells. *Cell Stem Cell*. 2015; 16:373–85. PMID: 25772071. DOI: 10.1016/j.stem.2015.02.004 [PubMed: 25772071]
- Yusa K, Rashid ST, Strick-Marchand H, Varela I, Liu PQ, Paschon DE, Miranda E, Ordonez A, Hannan NR, Rouhani FJ, Darche S, Alexander G, Marciniak SJ, Fusaki N, Hasegawa M, Holmes MC, Di Santo JP, Lomas DA, Bradley A, Vallier L. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. *Nature*. 2011; 478:391–4. PMID: 21993621. DOI: 10.1038/nature10424 [PubMed: 21993621]
- Zeng H, Guo M, Martins-Taylor K, Wang X, Zhang Z, Park JW, Zhan S, Kronenberg MS, Lichtler A, Liu HX, Chen FP, Yue L, Li XJ, Xu RH. Specification of region-specific neurons including forebrain glutamatergic neurons from human induced pluripotent stem cells. *PLoS One*. 2010; 5:e11853. PMID: 20686615. doi: 10.1371/journal.pone.0011853 [PubMed: 20686615]
- Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezchnikov AA, Zhang C, Xie T, Tran L, Dobrin R, Fluder E, Clurman B, Melquist S, Narayanan M, Suver C, Shah H, Mahajan M, Gillis T, Mysore J, MacDonald ME, Lamb JR, Bennett DA, Molony C, Stone DJ, Gudnason V, Myers AJ, Schadt EE, Neumann H, Zhu J, Emilsson V. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. *Cell*. 2013; 153:707–20. PMID: 23622250. DOI: 10.1016/j.cell.2013.03.030 [PubMed: 23622250]
- Zhang D, Pekkanen-Mattila M, Shahsavani M, Falk A, Teixeira AI, Herland A. A 3D Alzheimer's disease culture model and the induction of P21-activated kinase mediated sensing in iPSC derived neurons. *Biomaterials*. 2014; 35:1420–8. PMID: 24290439. DOI: 10.1016/j.biomaterials.2013.11.028 [PubMed: 24290439]
- Zhang F, Wen Y, Guo X. CRISPR/Cas9 for genome editing: progress, implications and challenges. *Hum Mol Genet*. 2014; 23:R40–6. PMID: 24651067. DOI: 10.1093/hmg/ddu125 [PubMed: 24651067]
- Zhang F, Wang LP, Boyden ES, Deisseroth K. Channelrhodopsin-2 and optical control of excitable cells. *Nat Methods*. 2006; 3:785–92. doi: nmeth936 [pii] 10.1038/nmeth936. PMID: 16990810. [PubMed: 16990810]
- Zhang N, An MC, Montoro D, Ellerby LM. Characterization of Human Huntington's Disease Cell Model from Induced Pluripotent Stem Cells. *PLoS Curr*. 2010; 2:RRN1193. PMID: 21037797. doi: 10.1371/currents.RRN1193 [PubMed: 21037797]
- Zhang Q, Yu JT, Zhu QX, Zhang W, Wu ZC, Miao D, Tan L. Complement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease. *Brain Res*. 2010; 1348:216–21. PMID: 20558149. DOI: 10.1016/j.brainres.2010.06.018 [PubMed: 20558149]
- Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keefe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Barres BA, Wu JQ. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J Neurosci*. 2014; 34:11929–47. PMID: 25186741. DOI: 10.1523/JNEUROSCI.1860-14.2014 [PubMed: 25186741]
- Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy J, Xu W, Yang N, Danko T, Chen L, Wernig M, Südhof TC. Rapid Single-Step Induction of Functional Neurons from Human Pluripotent Stem Cells. *Neuron*. 2013; 78:785–798. doi: papers2://publication/doi/10.1016/j.neuron.2013.05.029. [PubMed: 23764284]
- Zhou T, Benda C, Dunzinger S, Huang Y, Ho JC, Yang J, Wang Y, Zhang Y, Zhuang Q, Li Y, Bao X, Tse HF, Grillari J, Grillari-Voglauer R, Pei D, Esteban MA. Generation of human induced

pluripotent stem cells from urine samples. *Nat Protoc.* 2012; 7:2080–9. PMID: 23138349. DOI: 10.1038/nprot.2012.115 [PubMed: 23138349]

Zhu Z, Gonzalez F, Huangfu D. The iCRISPR platform for rapid genome editing in human pluripotent stem cells. *Methods in enzymology.* 2014; 546:215–50. PMID: MEDLINE:25398343. DOI: 10.1016/b978-0-12-801185-0.00011-8 [PubMed: 25398343]


Zou J, Maeder ML, Mali P, Pruett-Miller SM, Thibodeau-Beganny S, Chou BK, Chen G, Ye Z, Park IH, Daley GQ, Porteus MH, Joung JK, Cheng L. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. *Cell Stem Cell.* 2009; 5:97–110. PMID: 19540188. DOI: 10.1016/j.stem.2009.05.023 [PubMed: 19540188]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 1. Using human patient derived induced pluripotent stem (iPS) cells to model Alzheimer's disease (AD) pathology**

This model figure illustrates the logical path of experiments using iPS cells to study AD phenotypes and screen for novel therapeutics. Somatic cells (blood, skin, etc.) are reprogrammed *in vitro* into iPS cell colonies. At this point, or later, genome-editing techniques can be used to create isogenic lines containing specific mutations or transgenes. Techniques exist to differentiate the iPS cells into neural cells that include neurons, microglia, astrocytes and oligodendrocytes, as well as neural progenitor cells (not pictured). From the iPS cell stage, self-organizing tissue cytosystems, or organoids, can also be created in three-dimensional culture. Neural cells differentiated from iPS lines with sporadic or familial AD (sAD or fAD) backgrounds can display a number of AD-like phenotypes that can be assayed *in vitro*. These include amyloid  $\beta$  peptide production and, in the case of three-dimensional culture, amyloid plaques, tau pathology, synaptic dysfunction, immune activation, genomic instability, and aberrant endosome trafficking. High-throughput screens can be designed to examine the impact of small molecule or other treatments upon these and other AD-like phenotypes directly in human neural cells. The development of novel treatments for the AD patient and the success of these treatments in the clinic completes the cycle.



Table 1

Literature reviewed.

Reference	Lab*	Year	PMID	Cell Source	Disease	Mutation/Gene	Genome Editing/Iso genic lines	Cell Types Examined	Phenotypes Reported	Drug treatment	Profiling
Yagi et al., 2011	Suzuki	2011	21900357	iPSCs from Coriell hFib: AG07768, AG09908; Clone 201B7/1	fAD, sporadic PD	<i>PSEN1</i> A246E, <i>PSEN2</i> N141I		Neurons	A $\beta$	Compound E, Compound W	Gene expression microarray
Liu et al., 2011	Izpisua Belmonte	2011	21346760	H9 ESCs; iPSCs from BJ hFib, Coriell hFib: AG01972, AG11498, AG06297, GM00038, AG05247, AG09602.	HGPS progeria	<i>LMNA</i> G608G		Smooth muscle cells	Premature senescence, nuclear defects		DNA methylation microarray
Israel et al., 2012	Goldstein	2012	22278060	iPSCs from primary patient hFibs	fAD, sAD	<i>APP</i> duplication		NPCs, neurons	A $\beta$ , Tau, GSK3 $\beta$ activity, Endosomes, Vesicle trafficking, Synapse formation/ function	Compound E, DAPT	Gene expression microarray
Koch et al., 2012	Walter	2012	22510327	ESCs: I3 (TE03); iPSCs: PKa <sup>2</sup>	fAD,	Overexpression of <i>PSEN1</i> /L166P and D385N		It-NES cells, NPCs, neurons	A $\beta$ , NPC proliferation	DAPT, ibuprofen indomethacin	
Maclean et al., 2012	Orkin	2012	23045682	ESCs: CSES2 and CSE13.3; iPSCs: DS2, DS1 MRC5-IPS74	DS	Trisomy 21	Spontaneous disomic isogenic lines	Hematopoietic cells	A $\beta$ , hematopoiesis		
Shi et al., 2012	Livesey	2012	22344463	ESCs: DS-ES SC-321, H9; iPSCs: DS1-iPS44	DS	Trisomy 21		NPCs, neurons	A $\beta$ , aggregates, Tau	DAPT	
Kondo et al., 2013	Inoue	2013	23434393	iPSCs from primary patient hFibs	fAD, sAD	<i>APPE693</i> and V717L		Neurons, astrocytes	A $\beta$ , Cellular/oxidative stress,	DHA, DBM14-26, NSC23766, BACE inhibitor IV (BSI)	Gene expression microarray

Reference	Lab*	Year	PMID	Cell Source	Disease	Mutation/Gene	Genome Editing/Iso genic lines	Cell Types Examined	Phenotypes Reported	Drug treatment	Profiling
Fong et al., 2013	Huang	2013	24319659	iPSCs from primary patient hFibs	FTD	<i>MAPT</i> A152T	Zinc finger nucleases	NPCs,	Tau, Neural degeneration, Dopaminergic phenotypes		
Xu et al., 2013	Zhong	2013	23305945	ESCs: H9, iPSCs: hiPS-C4 line, iCell Neurons.	AD	Exogenous A $\beta$		NPCs, neurons	Neuronal viability, Cell cycle, Neurogenesis, Differentiation	Cdk inhibitors	Compound screen
Weick et al., 2013	Bhattacharyya	2013	23716668	iPSCs from Cortell hFib: AG05397, GM02504.	DS	Trisomy 21	Disomic isogenic cells via mosaicism	NPCs, neurons	Cellular/oxidative stress, Synapse formation/ function		Gene expression microarray
Miller et al., 2013	Studer	2013	24315443	iPSCs from Cortell hFib: AG06917, AG06297, AG11498	HGPS Prgeria, PD	<i>LMNA</i> C1824T; <i>PINK1</i> Q456X; <i>Parkin</i> V324A.		Neurons	Cellular/oxidative stress, Cellular aging, Lewy-body-precursor-like inclusions, DNA damage, Mitochondrial dysfunction		RNA-Seq
Choi et al., 2014	Kim	2014	25307057	ReN cell VM human neural stem (ReN) cells (Millipore)	fAD	Overexpression of <i>APP</i> K670N/M671L/V717I; <i>PSEN1</i> ( E9)		3D neural culture in Matrigel	A $\beta$ , Tau, Neural degeneration	Compound E, BACE inhibitor IV (BSI), DAPT, SGSM41	
Hbaoui et al., 2014	Feki	2014	24375627	iPSCs from primary patient hFibs	DS	Trisomy 21	Isogenic cells from discordant monozygotic twins	NPCs, neurons, neurospheres	Synapse number, NPC Viability, DYRK1A activity, Neurogenesis, Differentiation	epigallocatechin gallate (EGCG)	RNA-Seq
Muratore et al., 2014	Young-Pearse	2014	24524897	iPSCs; hFibs from HSCI	fAD	<i>APP</i> V717I		iPSCs, NPCs, Neurons	A $\beta$ , Tau, APP cleavage, Endosomes	DAPT, Compound E, BACE inhibitor C3, Anti-A $\beta$ antibodies	Nanostring gene expression array
Sproulet et al., 2014	Noggle	2014	24416243	iPSCs; hFibs from Cortell AG07671, AG07768, AG08446	fAD	<i>PSEN1</i> A246E, M146L		iPSCs, NPC's, neurons	A $\beta$ , differentiation	<i>Recombinant Norrin</i>	Gene expression microarray
Wren et al., 2015	Bu	2015	26373282	iPSCs from primary patient hFibs	FTD	<i>MAPT</i> N279K		NPCs	Tau, Endosomes, Vesicle trafficking, Cellular/oxidative stress		
Iovino et al., 2015	Spillantini	2015	26220942	iPSCs from primary patient	FTD	<i>MAPT</i> N279K, P301L		Neurons	Tau, Mitochondrial dysfunction, $\alpha$ -synuclein,		RNA-Seq

Reference	Lab*	Year	PMID	Cell Source	Disease	Mutation/Gene	Genome Editing/Iso genic lines	Cell Types Examined	Phenotypes Reported	Drug treatment	Profiling
Young et al., 2015	Goldstein	2015	25772071	hFibs, Coriell hFib: ND32854, ND40076	sAD	SORL1 SNPs		NPCs, neurons	Neurogenesis, Differentiation		
Murray et al., 2015	Nizetic	2015	25694335	Young adult hFibs from Galliera Genetic Bank	DS		Disomic isogenic cells via mosaicism	Neurons, hematopoietic cells	A $\beta$ , Mitochondrial dysfunction, DNA damage, proliferation		
Chang et al., 2015	Su	2015	25735452	ESCs: TWI iPSCs: atlantic fluid-derived	DS	Trisomy 21		NPCs, neurons	A $\beta$ , aggregates, Tau, Wnt signaling	F127-Bdph	
Hossini et al., 2015	Adjaye	2015	25765079	ESCs: H1, H9 iPSCs: NPH-46 hFibs	sAD			NPCs/neurons	Tau, gene expression	Compound E	Gene expression microarray

\* Corresponding Author: PMID: PubMed ID. hFib: Human fibroblast. iPSCs: Induced pluripotent stem cell. ESCs: Embryonic stem cell. sAD/fAD = sporadic/familial Alzheimer's disease. PD = Parkinson's disease. HGPS = Hutchinson-Gilford Progeria syndrome. FTD = Frontotemporal Dementia. DS = Down syndrome. NPCs = neural progenitor cells. HSCI = Harvard Stem Cell Institute.

<sup>1</sup> Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131, 861-872 18035408

<sup>2</sup> Falk, A., Koch, P., Kesavan, J., Takashima, Y., Ladewig, J., Alexander, M., Wiskow, O., Tailor, J., Trotter, M., Pollard, S., Smith, A. & Brustle, O. (2012). Capture of neuroepithelial-like stem cells from pluripotent stem cells provides a versatile system for in vitro production of human neurons. *PLoS One* 7, e29597 22272239

<sup>3</sup> Biancotti, J. C., Narwani, K., Buehler, N., Mandefro, B., Golan-Lev, T., Yamuka, O., Clark, A., Hill, D., Benvenisty, N. & Lavon, N. (2010). Human embryonic stem cells as models for aneuploid chromosomal syndromes. *Stem Cells* 28, 1530-1540 20641042

<sup>4</sup> Park, I. H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K. & Daley, G. Q. (2008). Disease-specific induced pluripotent stem cells. *Cell* 134, 877-886 18691744